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Abstract: Protein misfolding and aggregation diseases such as Alzheimer’s, Parkinson’s or prion diseases
are devastating neurodegenerative disorders that strongly affect the ageing population. Prolonged life
expectancy and the fact that age represents a crucial risk factor for these disorders will exacerbate the
problem in the future. As a consequence, there is an urgent need for diagnostic tests that allow early and
reliable diagnosis of these diseases. The main pathological hallmark of protein misfolding and aggregation
diseases is the accumulation of proteins as amyloid aggregates. Recently developed biochemical assays aim
to amplify and detect small amounts of protein aggregates for disease diagnosis. These assays are based
on the self-replication properties of amyloid aggregates, which enable the amplification and detection
of minute amounts of amyloid aggregates. My thesis focuses on the development of innovative amyloid
amplification assays that enable not only the sensitive detection but also the absolute quantification
of amyloid aggregates. I have developed amyloid amplification assays for three different amyloidogenic
proteins including insulin, prion protein, and ￿-synuclein. In the first part of this thesis, I describe the de-
velopment of a digital amyloid am-plification assay for the sensitive detection and absolute quantification
of insulin amyloid aggregates. I used droplet-based microfluidics to encapsulate thousands of individual
amplification reactions into small, uniform reaction compartments. Parallel, template-catalysed amplifi-
cation led to the formation of large aggregates in droplets that initially encapsulated amyloid propagons.
The number of propagons in the analyte was calculated from the fraction of aggregate-positive droplets
of different dilutions of the analyte. The high number of replicate reactions yielded large, highly accu-
rate data sets for rapid digital analysis using low reagent volumes. The assay proved to be a reliable
and precise tool for the detection of single amyloid propagons, and for the absolute quantification of
propagon numbers. The second part of my thesis focuses on the establishment and application of the
real-time quaking-induced conversion (RT-QuIC) assay, an amyloid amplification assay for prion protein.
RT-QuIC allows the detection of small amounts of the scrapie prion protein through seeded conversion of
the cellular prion protein. In the first step, I implemented and validated the diagnostic RT-QuIC on cere-
brospinal fluid samples from patients with suspected Creutzfeldt-Jakob disease. Samples from suspected
cases were analysed by RT-QuIC, and the results were confirmed with autopsy results. Furthermore, I
adapted the RT-QuIC assay to assess inactivation of prions adsorbed to surgical steel surfaces. Inactiva-
tion of prions adsorbed to surgical steel is crucial to reduce the potential risk of iatrogenic transmission of
prion infectivity. A new formulation composed of hypochlorite, phosphate, silicate and phosphonate was
identified as a potential decontaminant for prions bound to surgical steel. Finally, the assay was used
to investigate prion self-replication in cerebellar organotypic cultured slices treated with neurotoxic anti-
prion antibodies. The results showed that neurotoxic anti-prion antibodies do not induce self-replication
of prions, but rather act downstream of prion self-replication. In the last part of my thesis, I describe the
development of an ￿-synuclein amyloid amplification assay that can detect minimal amounts of ￿-synuclein
aggregates. The assay has been used to investigate the inactivation of ￿-synuclein aggregates bound to
stainless steel. Treatment with formic acid and sodium hypochlorite achieved effi-cient inactivation of
￿-synuclein propagons. Furthermore, the ￿-synuclein amyloid amplification assay was adapted to detect
pathological aggregates in blood samples of affected patients. Different pretreatments were tested to
enrich low-abundance aggregates in blood. Immunoprecipitation with specific anti-￿-synuclein antibod-
ies was the most efficient treatment. Applying this treatment, I could demonstrate that samples from
Parkinson’s disease patients showed low-level propagation activity in the amplification assay. The highly
sensitive amyloid amplification assays developed in my thesis enabled the detection of minute amounts of
pathological protein aggregates. A digital droplet-based amplification assay further allowed the determi-
nation of the absolute number of amyloid propagons in an analyte and the detection of single propagation
units. These assays hold great potential for the early diagnosis of protein misfolding and aggregation
diseases. In addition, the assays will help us to gain a more profound understanding of the molecular
mechanisms underlying neurodegeneration.
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Summary
Protein misfolding and aggregation diseases such as Alzheimer’s, Parkinson’s or
prion diseases are devastating neurodegenerative disorders that strongly a ect the
ageing population. Prolonged life expectancy and the fact that age represents a
crucial risk factor for these disorders will exacerbate the problem in the future. As
a consequence, there is an urgent need for diagnostic tests that allow early and
reliable diagnosis of these diseases. The main pathological hallmark of protein
misfolding and aggregation diseases is the accumulation of proteins as amyloid
aggregates. Recently developed biochemical assays aim to amplify and detect small
amounts of protein aggregates for disease diagnosis. These assays are based on
the self-replication properties of amyloid aggregates, which enable the amplification
and detection of minute amounts of amyloid aggregates.
My thesis focuses on the development of innovative amyloid amplification assays
that enable not only the sensitive detection but also the absolute quantification
of amyloid aggregates. I have developed amyloid amplification assays for three
di erent amyloidogenic proteins including insulin, prion protein, and ↵-synuclein.
In the first part of this thesis, I describe the development of a digital amyloid am-
plification assay for the sensitive detection and absolute quantification of insulin
amyloid aggregates. I used droplet-based microfluidics to encapsulate thousands of
individual amplification reactions into small, uniform reaction compartments. Parallel,
template-catalysed amplification led to the formation of large aggregates in droplets
that initially encapsulated amyloid propagons. The number of propagons in the
analyte was calculated from the fraction of aggregate-positive droplets of di erent
dilutions of the analyte. The high number of replicate reactions yielded large, highly
accurate data sets for rapid digital analysis using low reagent volumes. The assay
proved to be a reliable and precise tool for the detection of single amyloid propagons,
and for the absolute quantification of propagon numbers.
The second part of my thesis focuses on the establishment and application of the
real-time quaking-induced conversion (RT-QuIC) assay, an amyloid amplification
assay for prion protein. RT-QuIC allows the detection of small amounts of the scrapie
prion protein through seeded conversion of the cellular prion protein. In the first step,
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I implemented and validated the diagnostic RT-QuIC on cerebrospinal fluid samples
from patients with suspected Creutzfeldt-Jakob disease. Samples from suspected
cases were analysed by RT-QuIC, and the results were confirmed with autopsy
results. Furthermore, I adapted the RT-QuIC assay to assess inactivation of prions
adsorbed to surgical steel surfaces. Inactivation of prions adsorbed to surgical steel
is crucial to reduce the potential risk of iatrogenic transmission of prion infectivity. A
new formulation composed of hypochlorite, phosphate, silicate and phosphonate
was identified as a potential decontaminant for prions bound to surgical steel. Finally,
the assay was used to investigate prion self-replication in cerebellar organotypic
cultured slices treated with neurotoxic anti-prion antibodies. The results showed that
neurotoxic anti-prion antibodies do not induce self-replication of prions, but rather
act downstream of prion self-replication.
In the last part of my thesis, I describe the development of an ↵-synuclein amyloid
amplification assay that can detect minimal amounts of ↵-synuclein aggregates. The
assay has been used to investigate the inactivation of ↵-synuclein aggregates bound
to stainless steel. Treatment with formic acid and sodium hypochlorite achieved e -
cient inactivation of ↵-synuclein propagons. Furthermore, the ↵-synuclein amyloid
amplification assay was adapted to detect pathological aggregates in blood samples
of a ected patients. Di erent pretreatments were tested to enrich low-abundance
aggregates in blood. Immunoprecipitation with specific anti-↵-synuclein antibodies
was the most e cient treatment. Applying this treatment, I could demonstrate that
samples from Parkinson’s disease patients showed low-level propagation activity in
the amplification assay.
The highly sensitive amyloid amplification assays developed in my thesis enabled
the detection of minute amounts of pathological protein aggregates. A digital droplet-
based amplification assay further allowed the determination of the absolute number
of amyloid propagons in an analyte and the detection of single propagation units.
These assays hold great potential for the early diagnosis of protein misfolding and
aggregation diseases. In addition, the assays will help us to gain a more profound
understanding of the molecular mechanisms underlying neurodegeneration.
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Zusammenfassung
Neurodegenerative Erkrankungen wie Alzheimer, Parkinson oder Prionenerkrankun-
gen gehören zu den verheerendsten Krankheiten im Alter. Da die Häufigkeit der
Erkrankungen mit steigendem Alter zunimmt, stellen neurodegenerative Krankheiten
eine grosse Herausforderung für die alternde Gesellschaft mit stetig steigender
Lebenserwartung dar. Entsprechend hoch ist das Bedürfnis nach verlässlichen
Methoden zum Nachweis dieser Erkrankungen. Neurodegenerative Erkrankungen
sind durch die Ablagerung von fehlgefalteten Proteinen in sogenannten Amyloidag-
gregaten gekennzeichnet. Kürzlich entwickelte, biochemische Verfahren zur Diag-
nose von Proteinfehlfaltungserkrankungen zielen darauf ab, kleinste Mengen von
Amyloidaggregaten zu vervielfältigen und so deren Detektion zu ermöglichen. Diese
Verfahren beruhen auf der Fähigkeit zur Selbstreplikation von Amyloidaggregaten,
bei welcher Keime von fehlgefalteten Proteinen die Umwandlung von natürlich gefal-
teten Proteinen in wachsende Amyloidaggregate verursachen.
In meiner Dissertation habe ich mich mit der Entwicklung von innovativen Tests zur
Vervielfältigung von Amyloidaggregaten, die neben dem empfindlichen Nachweis
von Aggregaten auch deren Quantifizierung ermöglichen, beschäftigt.
Im ersten Teil beschreibe ich die Entwicklung eines Tests zur Quantifizierung von
einzelnen Insulinaggregaten. Tausende mikroskopisch kleine Tröpfchen dienten
als Reaktionsbehälter für die Nachweisreaktionen von Amyloidaggregaten. In je-
dem dieser Tröpfchen fand eine einzelne Vervielfältigungsreaktion statt, so dass zu
Reaktionsende all jene Tröpfchen, die zu Beginn ein Aggregat enthielten, grosse,
deutlich erkennbare Aggregate umschlossen. Aus dem Anteil der Tröpfchen mit neu
gebildeten Aggregaten liess sich mittels digitaler Analyse die Anzahl ursprünglicher
Aggregate in der Analytlösung berechnen. Durch die grosse Anzahl paralleler
Reaktionen in den Mikrotröpfchen war es möglich, einzelne Amyloidaggregate
nachzuweisen und präzise zu zählen.
Im zweiten Teil beschreibe ich verschiedene Anwendungen des ’Real-Time Quaking-
Induced Conversion’ (RT-QuIC) Verfahrens, einer Nachweismethode für Prion-
aggregate. Der Nachweis basiert auf der Umwandlung des zellulären Prionpro-
teins in fehlgefaltetes Prionprotein durch die Zugabe von Keimen des fehlgefal-
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teten Prionproteins. Zunächst habe ich die Methode zur Diagnose von Gehirn-
Rückenmarksflüssigkeit bei Patienten mit Verdacht auf Creutzfeldt-Jakob-Krankheit
eingeführt und validiert. Verdachtsfälle wurden mit der RT-QuIC Methode analysiert
und die Resultate mittels Autopsiedaten bestätigt. In einem weiteren Schritt habe ich
die RT-QuIC Methode verwendet, um die Inaktivierung von Prionen auf Oberflächen
aus chirurgischem Stahl zu untersuchen. Die besten Dekontaminierungsergebnisse
erzielte eine Formulierung aus Hypochlorit, Phosphat, Silikat und Phosphonat. In
einer weiteren Anwendung habe ich mittels RT-QuIC untersucht, ob neurotoxische
Anti-Prion-Antikörper zur Neubildung von fehlgefalteten Prionaggregaten führen
können. Die Untersuchung von behandelten organotypischen Kleinhirnschnitten
zeigte, dass die Antikörper keine Selbstreplikation von Prionen auslösen, sondern
vielmehr auf nachfolgende Prozesse wirken.
Im dritten Teil beschreibe ich die Entwicklung eines Tests zur Vervielfältigung min-
imaler Mengen von ↵-Synukleinaggregaten. Mithilfe dieses Tests habe ich die
Inaktivierung von ↵-Synukleinaggregaten auf Oberflächen aus chirurgischem Stahl
untersucht. Ameisensäure und Natriumhypochlorit waren die wirksamsten der
getesteten Dekontaminierungsmittel. Des Weiteren habe ich den Test für den Nach-
weis von pathologischen ↵-Synukleinaggregaten in Blutproben angepasst. Dazu
habe ich verschiedene Vorbehandlungsmethoden zur Anreicherung der Aggregate
getestet. Die Fällung von Aggregaten mittels spezifischer Antikörper erwies sich am
erfolgreichsten, so dass in Proben von Parkinson-Patienten geringfügige Aggregat-
Vervielfältigung nachgewiesen werden konnten.
Die empfindlichen Nachweisverfahren für Amyloidaggregate, die ich entwickelt habe,
ermöglichen den Nachweis von kleinsten Mengen an pathologischen Proteinaggre-
gaten. Basierend auf Tropfen-Mikrofluidik konnte der Nachweis von einzelnen Ag-
gregaten und die Bestimmung der exakten Anzahl von Aggregationseinheiten erzielt
werden. Die in dieser Dissertation beschriebenen Verfahren haben daher grosses
Potenzial zur diagnostischen Früherkennung von Proteinfehlfaltungserkrankungen.
Ausserdem erwarte ich, dass sie zu einem besseren Verständnis der molekularen
Mechanismen von neurodegenerativen Erkrankungen beitragen werden.
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1Introduction
1.1 Amyloid State of Proteins
1.1.1 Amyloid Structure
Protein aggregation is a widespread phenomenon in living organisms with both
physiological and deleterious functions. Over the last decades, there has been
growing interest in protein aggregation, mainly due to the association of protein
aggregation with a range of neurodegenerative disorders. Protein aggregation
involves self-association of soluble proteins to form insoluble, highly ordered fibrillar
aggregates referred to as ’amyloid’ (Chiti and Dobson, 2006; Eisenberg and Jucker,
2012). The term ’amyloid’ was introduced in the medical scientific literature by
the German pathologist Rudolf Virchow (1821-1902) to describe cerebral corpora
amylacea reacting with iodine-sulphuric acid, a stain conventionally used to detect
starch in plants. Virchow was convinced to have found structures made of starch, and
named them amyloid, referring to starch-like (Virchow, 1854). The name remained,
even though soon after its discovery, the main constituent of amyloid was shown to
be proteinaceous (Friedreich and Kekule, 1859).
Early structural studies used Congo red staining to identify the well-ordered, repetitive
structure of protein fibrils (Bennhold, 1922). Reactivity to the aniline dye Congo
red was a traditional criterion for amyloid, which has now been refined by structure-
related criteria mainly derived from X-ray crystallography (Eanes and Glenner, 1968;
Geddes et al., 1968). Amyloid fibrils are long, unbranched protein filaments (Cohen
and Calkins, 1959) with a typical cross-  spine architecture (Fig. 1.1). The basic
repeating unit of amyloid fibrils are  -strands that are stacked perpendicular to the
fibril axis and connected laterally by hydrogen bonds to form  -sheets in parallel to
1
the axis. The  -sheets are usually aligned ’in register’, which means that identical
side chains of consecutive peptides are placed on top of each other along the fibril
(Nelson et al., 2005). The continuous  -sheets constitute protofilaments, which
assemble into mature fibrils (Jiménez et al., 2002).
fibril axis
10 Å
4.8 Å
Fig. 1.1.: Architecture of amyloid fibrils (adapted from Serpell, 2014). Mature amyloid fibrils (right)
are composed of protofilaments (centre) intertwining due to hydrophobic interactions. Each
protofilament is made up of  -strands stacked perpendicular to the fibril axis forming two
 -sheets running parallel to the axis (left). Interstrand distances of 4.8 Å and intersheet
distances of 10 Å are characteristic for amyloid fibrils (Nelson et al., 2005; Eisenberg and
Jucker, 2012).
2 Chapter 1 Introduction
1.1.2 Models of Protein Misfolding and Amyloid Aggregation
Thermodynamics of Amyloid Formation
One of the unique properties of amyloid fibrils is their remarkably high level of
thermodynamic stability. The high stability makes the fibrillation process virtually
irreversible in the conditions under which the fibrils form. The main reason for the
great stability are strong intermolecular interactions (Nelson et al., 2005; Makin
et al., 2005; Knowles et al., 2007). Accordingly, the stability of the amyloid state is
dependent on the protein concentration. The stability of the monomeric, native state,
however, is independent of the protein concentration. Therefore, above a critical
concentration, the amyloid state is thermodynamically favoured over the native state
(Gazit, 2002; Knowles et al., 2014). The free energy of the amyloid state is lower
than the free energy of the native state (Fig. 1.2). The two states are separated by
an energy barrier, the activation energy, Ea. If the energy barrier is high enough, the
transition into the more stable amyloid state is prevented, and the protein remains
kinetically trapped in the native state. If the transition state is easily reached, the
native state spontaneously converts to the amyloid state.
Even though the native state is highly stable and thermodynamically favoured over
the unfolded state, in contrast to what was postulated by Anfinsen (Anfinsen, 1973),
the native state is a local minimum rather than the global minimum in the folding
energy landscape for a large number of proteins. The global minimumwith the lowest
free energy is represented by the amyloid state. The native state is a metastable
state with respect to the amyloid state, a local minimum separated from the global
minimum by an energy barrier (Gazit, 2002; Baldwin et al., 2011).
Under physiological conditions, the concentration of many amyloidogenic proteins
was found to be higher than the critical concentration (Baldwin et al., 2011), and
hence, the amyloid state is thermodynamically favoured over the native state. And
yet, native proteins do not constantly convert into aggregates. The relative stability of
the native state with respect to the amyloid state is therefore due to a kinetic barrier,
which prevents the uncontrolled formation of amyloid (Baldwin et al., 2011).
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Fig. 1.2.: Thermodynamic energy profile of amyloid formation. The di erence of free energy between
a protein in the native state and in the amyloid state is the Gibbs free energy change,  G,
of amyloid formation. The transition from the native state to the amyloid state requires the
activation energy, Ea, which represents an energy barrier to the high-energy transition state.
Kinetics of Amyloid Formation
The conversion of native proteins into amyloid aggregates is a complex, multistep
process with diverse intermediate states of interconverting species with di erent
polymerisation states. The underlying mechanistic pathways of amyloid assembly
have been unravelled with the help of chemical kinetics. Early kinetic studies in-
vestigating the polymerisation of proteins showed that polymer assembly can be
described by a two-step process (Oosawa and Kasai, 1962). The process involves
a nucleation step in which small growth-competent aggregates are formed from
monomeric proteins, and an elongation step in which monomeric protein is added
to the ends of a growing polymer (Fig. 1.3a). The integrated rate law formulated by
Oosawa and Kasai, 1962 describes the time evolution of the polymerisation process
considering the underlying processes of nucleation and elongation.
The nucleation-polymerisation model was further extended with two additional pro-
cesses responsible for the observed autocatalysis: heterogeneous nucleation (Fer-
rone et al., 1980; Bishop and Ferrone, 1984; Ferrone et al., 1985) and polymer
fragmentation (Wegner, 1982; Bishop and Ferrone, 1984). In both processes,
existing polymers are involved in the generation of new polymers. In secondary
nucleation processes, new polymers nucleate on the surface of existing filaments,
and fragmentation processes generate new growth-competent polymer ends by
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breaking existing filaments into smaller pieces (Fig. 1.3a). These early studies
comprehensively presented the microscopic processes of polymerisation, which
were subsequently used to describe protein aggregation and amyloid formation
(Ferrone, 1999; Collins et al., 2004; Tanaka et al., 2006).
To determine the relative contribution of the microscopic processes, the non-linear
rate equations underlying the aggregation process need to be solved. Knowles and
colleagues presented a general analytical solution to the master equation describing
the kinetics of amyloid formation (Knowles et al., 2009; Cohen et al., 2011; Cohen
et al., 2012). Macroscopically, amyloid formation typically follows a sigmoidal curve
with an initial lag phase followed by an exponential growth phase and a plateau
phase (Fig. 1.3b). Comparing this theoretical kinetic description with experimental
Fig. 1.3.: (a) Microscopic processes underlying amyloid fibrillation (adapted from Cohen et al., 2011).
The microscopic processes can be categorised into multiplication processes and growth
processes. Multiplication processes lead to an increase in the number of fibrils, and therefore
to an increase in the number of growth-competent ends. Growth processes generate new
fibril mass (Meisl et al., 2017). Multiplication processes can be primary processes depending
on the concentration of monomeric species (primary nucleation) or secondary processes
depending on the concentration of preexisting fibrils (secondary nucleation, fragmentation).
(b) Sigmoidal function describing the macroscopic time course of amyloid formation. The
curve is typically described by an initial lag phase followed by an exponential growth phase,
which ends in a plateau phase upon substrate depletion.
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data allows one to unravel the relative importance of the underlying microscopic
processes.
The use of chemical kinetics to decipher molecular mechanisms of amyloid aggrega-
tion has been applied to a variety of amyloidogenic proteins. Examples include the
study of the aggregation kinetics of A 40 and A 42 (Cohen et al., 2013; Meisl et al.,
2014), ↵-synuclein (Galvagnion et al., 2015; Flagmeier et al., 2016) and insulin
(Meisl et al., 2017). Moreover, the approach has enabled studies investigating the
e ect of aggregation inhibitors such as molecular chaperones. Using the kinetic
approach, the microscopic polymerisation events inhibited by a chaperone were
identified (Cohen et al., 2015; Arosio et al., 2016). Every microscopic process was
found to be individually targetable by specific molecular chaperones, which opens
up new perspectives for the rational design of aggregation inhibitors to interfere with
the molecular mechanisms of amyloid aggregation (Arosio et al., 2016).
From a functional perspective, the term ’propagon’ was introduced to describe
species capable of self-replication through conversion of monomeric proteins into
amyloid in a template-catalysed way (Cox et al., 2003; Aguzzi et al., 2013). The term
encompasses the totality of all propagation-active species. In this respect, it di ers
from the term ’nucleus’, which describes a merely kinetic rather than functional
entity.
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1.1.3 Protein Misfolding and Aggregation Diseases
The aggregation of proteins into amyloid fibrils and the accumulation of the fibrillar
aggregates are the underlying principles of many neurodegenerative and systemic
disorders. The common denominator of all of these diseases is the conversion of a
soluble, physiologically functional protein into fibrillar amyloid aggregates (Knowles
et al., 2014). The conversion of soluble protein into amyloid aggregates might
promote disease by a loss of function of the physiological form of the protein, or
by a gain of function of the aggregated form. Each protein misfolding disease is
characterised by a specific protein undergoing misfolding and aggregation.
To date, more than 40 diseases have been described that are associated with protein
misfolding and amyloid fibrillation (Chiti and Dobson, 2006). A selection of some
of the most common disorders is listed in Figure 1.4. The diseases are concep-
Fig. 1.4.: Examples of human diseases associated with protein misfolding and amyloid aggregation.
Partial list of neurodegenerative and non-neurodegenerative diseases associated with
amyloid formation including the aggregating protein and the location of aggregate deposition.
Table adapted from Ross and Poirier, 2004; Chiti and Dobson, 2006; Sipe et al., 2016.
1.1 Amyloid State of Proteins 7
tually split into neurodegenerative and non-neurodegenerative disorders. Amyloid
deposits in neurodegenerative diseases are primarily found in the central nervous
system mainly in the brain, while in non-neurodegenerative amyloidoses, protein
deposits accumulate in peripheral organs (Chiti and Dobson, 2006).
The disorders, which are particularly relevant for this thesis include prion dis-
eases, mainly Creutzfeldt-Jakob disease (CJD), ↵-synucleinopathies, and injection-
localised amyloidosis associated with insulin. A brief overview is given in the following
sections.
Human Prion Diseases and Their Diagnosis
Human prion diseases. Human prion diseases, also known as human transmissible
spongiform encephalopathies, are a group of neurodegenerative disorders, which
result from the misfolding and accumulation of the cellular prion protein (PrPC). The
diseases are clinically characterised by a rapidly progressive dementia accompa-
nied by movement disorders, ataxia and myoclonus (Aguzzi et al., 2008). The main
neuropathological hallmarks of prion diseases include vacuolation or spongiform
change, neuronal cell loss, reactive astrogliosis, and microglia activation (Budka
et al., 1995; Aguzzi and Zhu, 2017).
Human prion diseases are aetiologically classified into sporadic, inherited and
acquired forms (Collinge, 2001). Sporadic prion diseases, including sporadic
Creutzfeldt-Jakob disease (sCJD) and rarely sporadic fatal familial insomnia, ac-
count for the majority of cases (⇠85%). The cause of sporadic prion diseases is
unknown (Collinge, 2001). Inherited or genetic prion diseases are associated with in-
herited, pathologic germline mutations in the prion protein gene (PRNP) and account
for approximately 15% of cases (Collinge, 2001). Genetic forms of prion diseases
include genetic Creutzfeldt-Jakob disease (gCJD), Gerstmann-Sträussler-Scheinker
disease (GSS), and fatal familial insomnia (FFI). Acquired forms, including iatro-
genic Creutzfeldt-Jakob disease (iCJD), variant Creutzfeldt-Jakob disease (vCJD)
and kuru, are caused by the transmission of infectivity. These latter disease types,
however, are very rare (Will, 2003).
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Diagnosis of prion diseases. Human prion diseases are definitely diagnosed by post
mortem histological or biochemical detection of the misfolded scrapie prion protein
(PrPSc) in brain tissue. However, a set of diagnostic criteria for the ante mortem
diagnosis of CJD has been proposed by theWorld Health Organisation (WHO, 1998).
According to the WHO criteria, probable CJD is diagnosed in patients if presenting
with progressive dementia accompanied by two of the typical clinical symptoms
including myoclonus, visual or cerebellar disturbance, pyramidal/extrapyramidal
dysfunction, akinetic mutism, and a positive result in one of the approved diagnostic
tests (WHO, 1998). Diagnostic tests include a typical pattern in electroencephalog-
raphy (Steinho  et al., 2004) and magnetic resonance imaging (Zerr et al., 2009) or
the detection of the biomarker 14-3-3 protein in the cerebrospinal fluid (CSF; Collins
et al., 2000). These tests, however, are not specific to CJD, and definitive diagnosis
requires post mortem analysis of brain tissue. Recently developed biochemical
assays exploiting the self-propagation activity of pathological prions, such as the
RT-QuIC assay (see ’1.1.5 Amyloid Amplification Assays, Assays for the in vitro
Replication of Prions’), have the potential to be more accurate tools for the specific
diagnosis of CJD (Groveman et al., 2017), and might eventually be included in the
WHO diagnostic criteria for CJD.
↵-Synucleinopathies and Their Diagnosis
↵-Synucleinopathies. ↵-Synucleinopathies comprise a group of neurodegenerative
disorders that are characterised by the misfolding and accumulation of pathologic
↵-synuclein. The three main ↵-synucleinopathies include Parkinson’s disease (PD),
dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Common
clinical disease symptoms include progressive decline in motor, cognitive and auto-
nomic functions and behavioural changes (Martí et al., 2003). However, symptoms
vary across the di erent diseases and are dependent on the a ected brain areas and
structures. PD is mainly characterised by motor dysfunction with the three cardinal
symptoms resting tremor, bradykinesia and rigidity (Jankovic, 2008). Early lesions
primarily involve the accumulation of ↵-synuclein aggregates in the form of Lewy
bodies in dopaminergic neurons of the substantia nigra in the brainstem (Braak et al.,
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2003b). DLB patients present with cognitive impairment, dementia, hallucinations
and Parkinson-like symptoms (McKeith et al., 2005). Lewy bodies are predominantly
found across subcortical, paralimbic, and neocortical structures (Gomez-Tortosa
et al., 1999). MSA clinical symptoms include autonomic dysfunction, cerebellar
ataxia, corticospinal dysfunction and parkinsonism (Gilman et al., 1999). Early
lesions a ect brainstem, striatum, basal ganglia and cerebellum (Jellinger et al.,
2005). While in PD and DLB ↵-synuclein inclusions are found in neurons (Baba
et al., 1998), in MSA they are predominantly found as glial cytoplasmic inclusions
(Spillantini et al., 1998).
Diagnosis of ↵-synucleinopathies. ↵-Synucleinopathies are routinely diagnosed
based on clinical criteria. However, autopsy examination is required for neuropatho-
logical confirmation of the diagnosis. The confirmation criterion at autopsy is the
histopathological detection of ↵-synuclein inclusions in brain tissue (Gelb et al.,
1999). In practice, the clinical diagnosis of PD is based on the recognition of the
cardinal symptoms and responsiveness to levodopa (Gelb et al., 1999). In addition
to the clinical data, structural and functional neuroimaging has proven useful to
detect changes specific for ↵-synucleinopathies (Pyatigorskaya et al., 2014). In
advanced stages, classical cases of PD are diagnosed rather confidently. However,
the large heterogeneity in clinical presentation and the overlap in clinical symptoms
makes the di erential diagnosis of the various ↵-synucleinopathies very challenging,
particularly at early disease stages (Tolosa et al., 2006). Due to the inherent limita-
tions of clinical diagnostics, research has been directed towards the development of
novel diagnostic tools such as new biomarkers or biochemical assays. Very recently,
amplification assays for the detection of small quantities of ↵-synuclein aggregates
have been developed. Analogous to the amplification assays described for the
diagnosis of prion diseases, the self-propagation activity of ↵-synuclein was used to
amplify ↵-synuclein aggregates from brain tissue or CSF samples in these assays
(Fairfoul et al., 2016; Shahnawaz et al., 2017; Sano et al., 2017). Due to their high
sensitivity and specificity, these assays hold great potential for a more accurate and
reliable diagnosis of ↵-synucleinopathies.
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Iatrogenic Insulin-Associated Amyloidosis
Therapeutic insulin, used to treat diabetes patients, is conventionally administered
by subcutaneous injections or pump-regulated infusions (Matteucci et al., 2015).
In some patients, extracellular amyloid deposits consisting of aggregated insulin
were found at the site of injection. First reports of insulin amyloidosis described the
formation of amyloid formation following therapeutic insulin administration in diabetes
patients (Störkel et al., 1983; Dische et al., 1988). The aggregated protein was
identified as insulin by immunohistochemistry and amino acid sequencing (Dische
et al., 1988). Since the initial reports of injection-localised insulin amyloidosis, an
increasing number of case reports have recently been published in the specialised
literature (Nilsson, 2016).
The main clinical implication of insulin-derived amyloidosis is poor blood glucose
control caused by an impairment of insulin absorption. The absorption at an a ected
injection site is two-thirds lower than at a normal, una ected site (Nagase et al.,
2014). Accordingly, the administered insulin dose is too low to reduce blood glucose
levels, and hyperglycaemia can occur. Injection-localised amyloidosis is treated by
surgical ablation of amyloidomas and by avoiding further injections at the site of
amyloidosis (Gupta et al., 2015).
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1.1.4 Amyloid Proteins
Prion Protein and the Prion Hypothesis
Structure and function. The cellular human prion protein is a small, glycosylphos-
phatidylinositol anchored cell-surface protein encoded by the PRNP gene on chro-
mosome 20 (Sparkes et al., 1986). The protein is synthesised from a precursor
protein with an N-terminal signal sequence directing the protein to the endoplasmic
reticulum (Kretzschmar et al., 1986). The mature protein consists of 208 amino acids
(residues 23-230), which constitute two structurally and functionally distinct moieties
(Riek et al., 1997; Zahn et al., 2000): the N-terminal flexible tail (aa 23-124) and the
C-terminal globular domain (aa 125-230). The structurally disordered flexible tail
contains five tandem repeats of an octapeptide (octapeptide repeat, OR) flanked by
positively charged clusters (charge clusters 1 and 2, CC1 and CC2) on both sides,
and a hydrophobic region separating the flexible tail from the C-terminal globular
domain (Fig. 1.5a). The globular domain is structurally well ordered (Fig. 1.5b)
and consists of two  -strands and three ↵-helices connected by loop regions (Riek
et al., 1996; Zahn et al., 2000).
Despite extensive research e orts, the physiological function of the cellular prion
protein is still not fully understood. Recent studies have shown that PrPC plays a
central role in peripheral myelin maintenance (Bremer et al., 2010). The N-terminal
flexible tail of PrPC was found to interact specifically with the G-protein coupled
receptor Gpr126 on Schwann cells, thereby promoting nerve myelin maintenance
(Kü er et al., 2016). Many other functions in neuroprotection, development, memory
formation, circadian rhythm and others have been proposed and need to be revisited
in the future (Wulf et al., 2017).
Protein-only hypothesis. In 1982 Prusiner isolated the infectious agent suspected
of causing transmissible spongiform encephalopathies. He suggested that the in-
fectious particle consists only of protein and proposed the term ’prion’ to describe
the proteinaceous infectious particle (Prusiner et al., 1982). The scrapie-associated
form of the prion protein (PrPSc) was found to be particularly resistant to proteinase
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Fig. 1.5.: Sequence and structure of the human cellular prion protein. (a) Primary amino acid sequence.
Residues of the charge cluster 1 (CC1, turquoise), the octapeptide repeat (OR, green), the
charge cluster 2 (CC2, purple), and the hydrophobic domain (HD, yellow) are highlighted
(Béland and Roucou, 2012). (b) Schematic representation of the domain structure. The
protein consists of an N-terminal flexible tail (grey, residues 23-124) and a C-terminal
globular domain (dark blue, residues 125-230). CC1, OR, CC2, and HD are indicated. (c)
NMR structure of the cellular prion protein (PDB: 1QLX, Zahn et al., 2000). The N-terminal
domain is largely unstructured (grey line, modelled), whereas the C-terminal domain adopts
a globular fold (dark blue).
K (PK) digestion (Bolton et al., 1982) and to bind the amyloid specific dye Congo
red (Prusiner et al., 1983). The identification of a single gene encoding both the
prion protein extracted from healthy animals as well as the scrapie-associated PrPSc
provided evidence for the existence of two conformational isoforms with the same pri-
mary sequence: the cellular PrPC and the scrapie PrPSc (Basler et al., 1986). PrPSc
was shown to multiply through conversion of endogenous PrPC into the scrapie
isoform (Prusiner et al., 1990). Compelling evidence for the ’protein-only hypothesis’
was provided by Büeler and coworkers, who showed that mice lacking the cellular
isoform PrPC are resistant to scrapie infection and do not show disease symptoms.
They concluded that the scrapie pathology strictly depends on the presence of PrPC
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(Büeler et al., 1993). The final proof for the ’protein-only hypothesis’ was provided by
studies in which recombinantly produced PrP was converted into infectious PrPSc in
vitro (Diaz-Espinoza and Soto, 2010). Inoculation with synthetic PrP aggregates led
to neurologic dysfunction in transgenic mice (Legname et al., 2004) and wild-type
hamsters (Castilla et al., 2005b). These results showed that infectious prion agents
can be produced from pure recombinant protein.
The term ’prion’ refers strictly to infectious agents, which are transmissible to suscep-
tible hosts through serial passages (Prusiner et al., 1982; Aguzzi, 2009). In contrast,
the term ’prionoid’ has been introduced for protein aggregates with prion-like proper-
ties for which infectivity has not been demonstrated (Aguzzi, 2009). Prionoids can
self-propagate and spread transcellularly, but they are not transmitted from one host
to another (Aguzzi and Rajendran, 2009).
↵-Synuclein - a Prion-Like Protein
Structure and function. Human ↵-synuclein is a 140-amino acid small, acidic protein
encoded by the SNCA gene on chromosome 4 (Spillantini et al., 1995). The protein
was first described in 1988 as a neuron-specific protein localised to the presynapse
and the nucleus of nerve cells (Maroteaux et al., 1988). Its primary sequence is
subdivided into three domains: (1) the highly conserved N-terminus containing im-
perfect repeats of the hexameric ’KTKEGV’ motif, (2) the central hydrophobic, highly
amyloidogenic NAC (non-amyloid-  component of Alzheimer’s disease amyloid,
historically named by Uéda et al., 1993) domain, and (3) the C-terminal domain
enriched in acidic residues and prolines (Fig. 1.6a,b). In its soluble, monomeric
form, ↵-synuclein is intrinsically disordered and primarily composed of random
coils (Eliezer et al., 2001), while upon interaction with lipids the protein acquires
some secondary structure (Fig. 1.6c). Upon interaction with lipids, the N-terminal
repeat domain shifts to an amphipathic ↵-helix, which mediates binding to negatively
charged phospholipids in vesicles and membranes (Davidson et al., 1998). The
central, hydrophobic NAC domain is essential for aggregation and mediates the
conversion of ↵-synuclein from the native state to  -sheet rich amyloid aggregates
(Giasson et al., 2001). The largely unstructured C-terminal domain interacts with
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Fig. 1.6.: Sequence and structure of human ↵-synuclein. (a) Primary amino acid sequence. The
residues of the N-terminal, imperfect hexameric repeat region are highlighted. The C-terminal
region mainly consists of negatively charged amino acids. (b) Schematic representation of
the domain structure. The protein consists of the N-terminal repeat domain (red, residues
1-65; repeats marked in bordeaux), the central NAC domain (green, residues 66-95) and the
acidic C-terminal domain (blue, residues 96-140). (c) Crystal structure of lipid-bound human
↵-synuclein (PDB: 1XQ8, Ulmer et al., 2005). The N-terminal region adopts an amphipathic,
↵-helical conformation. The highly amyloidogenic, central NAC domain forms a helix, and
the C-terminus is largely unstructured.
both proteins and small molecules through its highly charged residues and is thought
to be crucial for chaperone-like activities of ↵-synuclein (Souza et al., 2000).
Although substantial e orts have been made to investigate the role of ↵-synuclein, its
exact physiological function is not yet fully understood. The localisation to presynap-
tic nerve terminals and the association with synaptic vesicles (Maroteaux et al., 1988)
suggest a role in vesicle transport and neurotransmitter release. ↵-Synuclein was
shown to stimulate synaptic activity by promoting soluble N-ethylmaleimide-sensitive
factor attachment protein receptor (SNARE) complex assembly for neurotransmitter
release in a chaperone-like manner (Burré et al., 2010). More recently, ↵-synuclein
has been described to stimulate the dilation of the exocytic fusion pore, thereby
promoting the fusion of secretory vesicles with the membrane and the release of
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neurotransmitters through exocytosis (Logan et al., 2017). An impairment of this
function in neurotransmitter release would a ect synaptic function and neuronal
communication.
Prion-like spreading of ↵-synuclein pathology. Emerging evidence indicates that a
prion-like mechanism underlies ↵-synuclein pathology involving cell-to-cell spread-
ing through self-propagation of pathological aggregates. The first report of in vivo
transmission of ↵-synucleinopathies was described in a study in which brain ho-
mogenates of a ected animals were intracerebrally inoculated into healthy trans-
genic ↵-synuclein mice. The inoculation of mice expressing aggregation prone
A53T mutated ↵-synuclein led to significant acceleration of the ↵-synuclein pathol-
ogy (Mougenot et al., 2012; Luk et al., 2012a). Similar findings were reported for
inoculations with synthetic ↵-synuclein fibrils assembled from recombinant human
↵-synuclein (Luk et al., 2012a). Furthermore, cell-to-cell transmission of ↵-synuclein
pathology was observed following intracerebral inoculation of synthetic ↵-synuclein
fibrils (Luk et al., 2012b) or insoluble ↵-synuclein from DLB patient brains (Masuda-
Suzukake et al., 2013) in wild-type nontransgenic mice. Animals infected with patho-
logical ↵-synuclein aggregates showed accumulation of endogenous ↵-synuclein
inclusions and developed clinical symptoms reminiscent of ↵-synucleinopathies
(Luk et al., 2012b; Masuda-Suzukake et al., 2013). In vivo imaging of individual neu-
rons revealed selective cell-death of neurons bearing ↵-synuclein inclusions, which
indicates a correlation between inclusion formation and cytotoxicity (Osterberg et al.,
2015). Recently, a molecular mechanism for cell-to-cell transmission and toxicity
of pathologic ↵-synuclein aggregates through receptor-mediated endocytosis has
been proposed. According to this mechanism, ↵-synuclein aggregates are bound
by lymphocyte-activation gene 3 (LAG3) and internalised through endocytosis (Mao
et al., 2016). These recently published studies add to a growing body of evidence
suggesting that prion-like propagation of ↵-synuclein aggregates, and possibly even
other amyloidogenic proteins, might cause infectivity in neurodegenerative disorders
(Aguzzi and Rajendran, 2009). Accordingly, ↵-synuclein is the prionoid most likely
to be reclassified as a bona fide prion.
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Insulin - a Model Protein for Amyloid Aggregation
Structure and function. Insulin is a small peptide hormone of 51 amino acids synthe-
sised from the biologically inactive precursor preproinsulin produced in the  -cells in
the pancreas (Chan et al., 1976). Preproinsulin is converted into proinsulin (Steiner
et al., 1967) and finally into insulin by proteolytic cleavage. Biologically active insulin
consists of two polypeptide chains. The two chains, the 21-aa long A chain and
the 30-aa long B chain are linked by two disulfide bridges (Fig. 1.7a). Both chains
contain ordered secondary structure elements that pack around a hydrophobic core
(Hua et al., 1995). In solution, insulin exists in a dynamic equilibrium of monomers,
dimers, tetramers, and hexamers (Je rey and Coates, 1966). Apart from associating
into higher-order assemblies under native conditions, insulin was found to assemble
into fibrils in acidic conditions or at elevated temperatures (Waugh, 1944; Waugh,
1946). The fibrils are formed from a partially unfolded intermediate conformation
derived from monomeric protein (Nielsen et al., 2001). Characterisation of the fibrils
revealed a cross-  structure characteristic for amyloid fibrils (Burke and Rougvie,
1972), which makes insulin a good model system to study amyloid formation.
Insulin is a key regulator of blood glucose levels. In response to elevated blood
glucose levels, insulin is secreted from  -cells in the pancreas to increase glucose
uptake and storage by muscle and fat, and to inhibit glucose production by the liver
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Fig. 1.7.: Sequence and structure of human insulin. (a) Primary amino acid sequence with disulfide
bridges (A7-B7, A20-B19, A6-A11) indicated. (b) NMR structure of human insulin (PDB:
2HIU, Hua et al., 1995).
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(Saltiel and Kahn, 2001). Glucose uptake is mediated by the glucose transporter
GLUT4, which is translocated from the intracellular space to the cell surface upon
insulin signalling (Huang and Czech, 2007). Defects in insulin signalling lead to
diabetes mellitus, one of the leading causes of death in many developed countries
(ADA, 2010). Diabetes mellitus is a group of metabolic diseases characterised by
abnormally high levels of blood glucose - hyperglycaemia. The two main forms of
diabetes are classified as type 1 and type 2 diabetes. While type 1 diabetes results
from defects in insulin production, type 2 diabetes is caused by insulin resistance
through impaired insulin signalling (ADA, 2010).
According to the WHO, diabetes can be treated by subcutaneous administration of
recombinant insulin (WHO, 2013). Therapeutic human insulin was the first pharma-
ceutical product produced by recombinant DNA technology (Johnson, 1983). Today
it is one of the best characterised therapeutic proteins. Along with an increasing
number of insulin analogues designed to improve pharmacokinetics, insulin is still
widely used in the treatment of diabetes mellitus patients.
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1.1.5 Amyloid Amplification Assays
Basic Principle of Amyloid Amplification Assays
The molecular organisation of amyloid fibrils builds the structural basis for the self-
propagating properties of amyloid fibrils (Baskakov, 2009). The cross-  structure of
amyloid fibrils acts as a template for fibril elongation through monomer addition to
both fibril ends. In this way, preexisting fibrils propagate their fibrillar conformation
to monomeric protein, which leads to the conversion of monomer into amyloid and
ultimately to amyloid growth. The combination of amyloid growth and multiplication
of the amyloid template leads to highly e cient amyloid amplification (Fig. 1.8).
Amyloid amplification assays exploit the autocatalytic amplification cycle to detect
minute levels of amyloid aggregates. Traces of amyloid aggregates propagate their
fibrillar conformation to monomeric substrate protein, which leads to a growth of
fibril mass at the expense of the monomeric substrate. The growing fibrils are
subsequently fragmented into smaller additional propagation units, each of which
conversion
fragmentation
elongation
+
amplification
cycle
monomeric protein
misfolded protein
Fig. 1.8.: Autocatalytic amplification cycle of amyloid proteins. When incubated with monomeric
protein (light blue spheres), amyloid aggregates (dark blue hexagons) self-propagate into
larger aggregates by incorporating the monomeric protein in a template-catalysed way.
Large amyloid aggregates can be broken into a higher number of smaller aggregates by
fragmentation. The newly formed aggregates constitute new reactive units or propagons,
which promote further self-replication of amyloid aggregates.
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can again grow into larger fibrils. Consecutive repetition of the cycle enables the
amplification of undetectably small amounts of amyloid aggregates to detectable
levels of fibrillar aggregates.
The same basic principle of amplification underlies many di erent assays that have
been described so far (Saborio et al., 2001; Colby et al., 2007; Wilham et al., 2010).
Early progress was made mainly in the field of prion replication, and subsequently
transferred to other amyloidogenic proteins. Adaptations of the experimental mech-
anism of fragmentation, the conditions for optimal elongation, and the monomeric
substrate protein have recently led to a stepwise improvement in the development
of amyloid amplification assays. In the following sections, the main achievements
are outlined.
Assays for the in vitro Replication of Prions
In vitro replication of prions. To recapitulate in vitro the mechanisms underlying
prion propagation observed in vivo, first attempts to convert the cellular prion protein
PrPC into the protease-resistant scrapie isoform PrPSc in cell-free systems were
described in the 1990s (Raeber et al., 1992; Kocisko et al., 1994; Caughey et al.,
1995). The first evidence for in vitro conversion of PrPC into PrPSc came from
experiments with radiolabelled PrPC incubated with a large excess of PrPSc. After
incubation of recombinant hamster 35S-PrPC with PrPSc purified from hamster brains
for two days, a form of 35S-radiolabelled, PK-resistant PrP was detected suggesting
the conversion of 35S-PrPC into a 35S-PrPSc-like form (Kocisko et al., 1994). The
PrPSc-like form displayed biochemical properties indistinguishable from brain derived
PrPSc. However, the PrPSc-like form generated in vitro did not propagate infectivity
in a mouse bioassay (Hill et al., 1999). The low conversion e ciency was shown to
depend on the incubation time as well as on the initial concentrations of PrPSc and
35S-PrPC (Caughey et al., 1995). Despite the reduced conversion e ciency and
infectivity transmission, these initial experiments demonstrated prion self-replication
in vitro and provided evidence for the ’protein-only’ hypothesis of prion formation.
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Protein misfolding cyclic amplification. Based on the self-replication principle, a
more e cient assay for in vitro replication of prions has been described a few years
later by Soto and colleagues (Saborio et al., 2001). The protein misfolding cyclic
amplification (PMCA) assay consists of alternated cycles of sonication multiplying
the number of PrPSc aggregates through fragmentation, followed by an incubation
phase in which the aggregates grow by recruiting more PrPC molecules. Conceptu-
ally analogous to DNA amplification by polymerase chain reaction (PCR), PMCA
drastically amplifies the levels of PK-resistant prion protein (PrPres) starting from
small amounts of template PrPSc purified from prion-infected hamster brains and
substrate PrPC from brain homogenates of healthy animals. Newly formed PrPres
is detected by immunoblotting following PK digestion of residual PrPC (Saborio
et al., 2001). The in vitro synthesised PrP aggregates have similar biochemical
and structural properties as PrPSc derived from prion-infected brains and have been
shown to propagate prion infectivity in a hamster bioassay (Castilla et al., 2005b).
Since its first description, the PMCA assay has constantly been adapted and im-
proved to detect PrPSc in tissue samples of di erent species. In one of the early
applications of the assay, Soto and colleagues adapted the assay to demonstrate
the presence of PrPres in brain tissue (Soto et al., 2005) and in blood (Castilla
et al., 2005a) of prion-infected hamsters. They were able to distinguish healthy
animals from intracerebrally prion-inoculated, sick animals even at very early, pre-
symptomatic stages of the disease (Soto et al., 2005; Saá et al., 2006a) using the
PMCA technology. Later, the assay was used to amplify PK-resistant PrPres from
urine of prion-infected hamsters (Gonzalez-Romero et al., 2008) and from whole
blood of presymptomatic, prion-infected mice (Tattum et al., 2010). It was further
refined to quantify concentrations of misfolded prion protein in brain, spleen, blood
and urine of prion-infected hamsters from the number of PMCA cycles required for
detection (Chen et al., 2010). More recently, the PMCA assay has been adapted
for the detection of prions in human tissues and body fluids. Especially remarkable
was the detection of prions in the blood of patients su ering from vCJD (Lacroux
et al., 2014; Concha-Marambio et al., 2016; Bougard et al., 2016).
At the same time, the assay has also undergone various technological modifications
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and improvements. The assay was improved by automation (Castilla et al., 2005a;
Saá et al., 2006b), and the e ciency of the assay was further enhanced through
improved amplification and a more sensitive readout. In PMCAb, the PrPC to PrPSc
conversion is increased tenfold through the introduction of teflon beads in the PMCA
reaction (Gonzalez-Montalban et al., 2011). In another approach, PrPSc is enriched
with super-paramagnetic nanoparticles prior to amplification (Miller and Supattapone,
2011). Concentrating PrPSc templates before amplification allowed a more rapid am-
plification. To improve the readout of the PMCA assay, Rubenstein and colleagues
combined the assay with a surround optical fibre immunoassay (SOFIA). SOFIA
uses specific monoclonal antibodies with a fibre optics-based fluorescence detection
system, which enables a more sensitive detection of PrPres after fewer rounds of
PMCA (Rubenstein et al., 2010).
However, the method has several disadvantages such as impractical sonication
steps, and tedious immunoblot readouts, and requires the use of tissue homogenates
as source of substrate protein. To overcome these shortcomings, the method was
further optimised.
Real-time quaking-induced conversion. A major breakthrough in prion amplification
assays was achieved by the use of recombinantly expressed prion protein as a
substrate and the change to automated tube shaking to induce multiplication of
PrPSc. The use of recombinant hamster PrP in the rPrP-PMCA allowed the detection
of PrPres in the CSF of prion-infected hamsters in 2-3 days (Atarashi et al., 2007),
and the substitution of automated shaking for sonication in the quaking-induced con-
version (QuIC) assay further decreased the assay duration to a single day (Atarashi
et al., 2008). This new method allowed the discrimination between healthy and
scrapie-a ected hamsters in less time with higher sensitivity and e ciency (Atarashi
et al., 2008).
Another important development was the introduction of the amyloid-specific dye
thioflavin T (ThT) for the readout of newly formed amyloid aggregates instead of
immunodetection. ThT staining in combination with amplification inside microplates,
as described in the amyloid seeding assay (ASA), dramatically facilitated the con-
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version assays by automating both the amplification process as well as the readout
(Colby et al., 2007). This idea was taken up by Caughey and colleagues, who
combined it with the previously described quaking-induced conversion method. The
resulting assay, termed real-time quaking-induced conversion (RT-QuIC), is a rapid
high-throughput assay, which has been adopted to quantify propagation activity of
prions (Wilham et al., 2010). The propagation or seeding activity is determined
from a series of dilutions of the original prion-containing sample. The seeding dose
(SD50) refers to the concentration at which 50% of replicate reactions are positive.
To validate the assay, prion infectivity was determined in brain tissue, CSF and
blood of prion-infected hamsters, sheep and deer (Wilham et al., 2010; Elder et al.,
2013). Apart from its quantitative measure, the RT-QuIC assay has been shown to
outperform other assays with respect to sensitivity and specificity, as well as with
a reduced number of spontaneously aggregating, false positive reactions (Wilham
et al., 2010).
Similar as described for the PMCA, the RT-QuIC technology has been constantly
refined and adapted to prions isolated from various tissues of di erent host organ-
isms. Most crucial was the adaptation of the assay to human patient samples, which
enables the use of the assay as a tool for diagnosis of CJD.
Diagnostic application of the RT-QuIC. The first diagnostic application of the RT-
QuIC was described in 2011 (Atarashi et al., 2011). In a proof-of-concept study,
CSF samples from 18 definite sCJD patients and 35 control patients were correctly
diagnosed with an improved version of the RT-QuIC (CSF RT-QuIC). Additional
185 samples were tested in a blinded study. The assay achieved a sensitivity of
more than 80% and a specificity of 100% (Atarashi et al., 2011). These results
were confirmed by many subsequent, independent studies conducted in di erent
laboratories around the world (McGuire et al., 2012; Orrú et al., 2015; Park et al.,
2016). The correct diagnosis of hundreds of sCJD cases and controls with RT-QuIC
indicate that the assay is a powerful tool for antemortem diagnosis of sCJD. The re-
producibility of the assay for diagnosing human prion diseases was further assessed
in multi-centered, international ringtrial studies (McGuire et al., 2016; Cramm et al.,
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Fig. 1.9.: Principle of diagnostic amyloid amplification assays. (a) Samples are collected from patients
suspected of su ering from a neurodegenerative disorder linked to protein aggregation.
These include brain homogenates prepared from brain biopsies and CSF samples from
lumbar puncture. (b) Patient samples are used to seed the amyloid amplification reaction.
Samples containing amyloid aggregates cause amplification of aggregates, which can be
detected using conventional amyloid dyes, such as ThT. Fluorescence-positive samples
indicate samples positive for the disease.
2016). Taken together, CSF samples of sCJD patients and control CSF samples
were analysed by RT-QuIC at 14 di erent study centres spread around the world.
Even though the involved laboratories used partly di erent recombinant substrate
proteins and di erent instrumentation, the results of all participants were in almost
perfect agreement. The complete inter-laboratory concordance of the RT-QuIC
results proves the diagnostic applicability of the assay.
The diagnostic RT-QuIC has further been optimised and refined over the past years.
The long assay duration (approximately 5 days), which is the main practical limitation
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of the conventional CSF RT-QuIC assay, was shortened in a refined version of the
assay (Orrú et al., 2015). Truncated hamster HaPrP90 231 substrate, an increased
incubation temperature, and the addition of trace amounts of SDS increased the
speed of the RT-QuIC conversion reaction by approximately one third. In addi-
tion, the diagnostic sensitivity and specificity were enhanced to 95% and 100%,
respectively (Orrú et al., 2015). The improved assay with the truncated hamster
substrate was validated in a study with a larger panel of CSF samples and was
directly compared to the conventional CSF RT-QuIC. The study included 113 CJD
patients and 64 control patients and demonstrated the advantages of the adapted
assay such as faster kinetics, shorter assay time and increased assay sensitivity
(Groveman et al., 2017). Furthermore, the RT-QuIC assay was adapted to detecting
prions in the olfactory epithelium collected from nasal brushings. Nasal brushings
from 31 patients su ering from sCJD were accurately diagnosed with a sensitivity of
97% and a specificity of 100% (Orrú et al., 2014). As nasal brushings are minimally
invasive, this assay has a great potential to further enhance CJD diagnostics. In
view of the recent technological advances and the high reliability, specificity and
sensitivity of the RT-QuIC assay, the diagnostic criteria of the WHOmight be adapted
to include RT-QuIC for the diagnosis of CJD in the future.
Amplification Assays for Other Amyloidogenic Proteins
The active progress in the development of amyloid amplification assays in the
prion field and the emerging concept of prion-like propagation of various disease-
associated proteins have promoted the development of conceptually similar ampli-
fication assays for a variety of di erent proteins. Most relevant are amplification
assays described for both Alzheimer’s disease (AD) linked proteins, amyloid   and
tau, and for ↵-synuclein, the protein aggregating in Parkinson’s disease.
Amyloid   (A ) and tau amplification assays. The first report of an A  amplifica-
tion assay described a significantly faster aggregation time course for aggregation
reactions spiked with brain homogenates from an AD mouse model compared to
reactions spiked with wild-type mouse brain homogenate (Du et al., 2011). A few
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years later, Soto and colleagues established conditions for an A  amplification assay
(Salvadores et al., 2014) that was able to detect A  oligomers in the CSF of AD
patients. The di erent aggregation kinetics of reactions spiked with CSF samples
containing pathologic A  oligomers and samples devoid of A  oligomers allowed
the discrimination of samples of AD patients from healthy patient samples (Sal-
vadores et al., 2014). Further development of the A  amplification assay enabled
the detection of A  oligomers in peripheral blood of AD transgenic mice and its
application in screening of drug candidates for their therapeutic e ects (Estrada
et al., 2016). Tau amplification assays have been used for the detection of misfolded
tau aggregates in brain homogenates from human AD patients (Meyer et al., 2014;
Saijo et al., 2017) and in CSF samples from patients su ering from Pick’s disease
(Saijo et al., 2017).
↵-Synuclein amplification assays. The first described amyloid amplification assay
for ↵-synuclein made use of synthetic ↵-synuclein fibrils to seed the conversion
of monomeric ↵-synuclein (Herva et al., 2014). Aggregates formed by the assay
were found to have biochemical and biophysical properties similar to in vivo ↵-
synuclein aggregates. Herva et al., 2014 applied the assay to screen di erent
anti-amyloid compounds and their e ect on the template-catalysed conversion of
monomeric ↵-synuclein. Later adaptations mainly aimed at the diagnostic detection
of ↵-synuclein aggregates in tissues and body fluids from patients su ering from
↵-synucleinopathies. Recent studies have reported the detection of pathologic
aggregates in the brain and CSF of PD, DLB and MSA patients with sensitivities of
around 90% and specificities of roughly 95% (Fairfoul et al., 2016; Shahnawaz et al.,
2017; Sano et al., 2017). The kinetic parameters measured in the amplification
assays indicated a negative correlation between aggregation onset in the assay and
disease severity and progression (Shahnawaz et al., 2017). ↵-Synuclein amplifica-
tion has also been used to address the question of di erent strains of ↵-synuclein
fibrillar conformations. The conformations of ↵-synuclein fibrils from two di erent
transgenic mouse strains were shown to faithfully propagate in the amplification
assay (Jung et al., 2017).
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1.2 Digital Microfluidics
Microfluidics, the science of manipulating small volume fluids inside micron-scale
channels, has emerged as a powerful platform for biochemical and medicinal analy-
ses. Miniaturisation provides the advantages of low analyte volumes, short analysis
times, and a high sensitivity (Whitesides, 2006). One of the main applications is
droplet-based or digital microfluidics, in which discrete droplets generated from
immiscible phases (mostly water-in-oil emulsions) serve as reaction compartments.
Highly monodisperse droplets with nanometer to micrometer diameter are generated
at kilohertz frequencies, and the reactions inside individual droplets can be analysed
independently (Guo et al., 2012). The large number of droplets allows parallel
processing and analysis of droplets, yielding large data sets required for digital data
analysis. Digital microfluidics, therefore, o ers great potential for parallelisation and
high-throughput (Guo et al., 2012).
The use of digital microfluidics has revolutionised biochemical and biomedical ana-
lytics by enabling qualitative and quantitative analysis of droplet content (Guo et al.,
2012; Basova and Foret, 2015). Digital microfluidics has mainly been applied for
nucleic acid research such as digital PCR (Beer et al., 2007; Kiss et al., 2008), next
generation sequencing (Lan et al., 2016), or microarray technology (Wang et al.,
2003; Situma et al., 2006). More recently, it has also been used for protein analysis
including biomarker detection studies (Mok et al., 2014), crystallisation (Zhu et al.,
2014), or studies on amyloid growth (Knowles et al., 2011).
Amongst the most powerful applications of digital microfluidics is droplet digital
polymerase chain reaction (ddPCR), a technique allowing the absolute quantifica-
tion of DNA molecules (Hindson et al., 2011). In ddPCR, a target DNA sample is
partitioned into a large number of discrete microdroplets representing individual
reaction compartments, and the droplets are subjected to parallel PCR amplification.
After endpoint amplification, droplets containing a target DNA molecule are counted
based on a target-specific fluorescence readout. Since target DNA molecules are
distributed randomly in the analyte, the number of molecules per reaction compart-
ment is described by the Poisson distribution (Collins et al., 2015). Accordingly,
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Poisson statistics is applied to calculate the DNA copy number in the analyte solution
without the use of a calibration curve. The quantification of target DNA molecules
using ddPCR is highly precise and sensitive, therefore representing a new tool for
accurate molecular diagnostics (Huggett et al., 2015).
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1.3 Motivation and Aims of the Thesis
Protein aggregation diseases are among the most significant disorders in the age-
ing population. Despite the high prevalence of these diseases, early and reliable
diagnostic tests remain still elusive. Over the last decade, assays for the amplifi-
cation and detection of small quantities of prion aggregates have been developed,
and successfully applied to prion diagnostics. However, these assays are mainly
restricted to the prion protein, and limited in throughput, robustness, and precision.
This thesis aims to advance the amyloid amplification assays of three di erent amy-
loid proteins including insulin, prion protein and ↵-synuclein. For each protein an
amplification assay was developed and applied to detect minute amounts of amyloid
aggregates.
My first aim was to establish a robust and precise assay for the quantitative analysis
of insulin amyloid aggregates. A few attempts to quantify propagation activity of
amyloid aggregates using amplification assays have been reported previously (Shi
et al., 2013; Henderson et al., 2015; Takatsuki et al., 2015). However, in all of these
studies the propagation activity has been quantified relative to a known standard
sample. The objective of this thesis was therefore to develop a sensitive assay
capable of quantifying amyloid propagons in absolute numbers. To achieve this
objective, I developed an insulin amyloid amplification assay with digital readout
using droplet-based microfluidics.
In a second project, I aimed to implement and optimise the RT-QuIC assay for prion
diagnostics and biomedical applications. This included (1) the application of the
assay to detect PrPSc in human body fluids and tissues for CJD diagnosis, (2) the
adaptation of the assay to study the inactivation of prions bound to surgical steel,
and (3) the assessment of prion self-replication in cerebellar organotypic cultured
slices treated with neurotoxic anti-prion antibodies. The above aims required the
adaptation of the RT-QuIC to detect PrP aggregates in samples di erent from the
commonly used brain homogenates or CSF samples.
1.3 Motivation and Aims of the Thesis 29
In the third part of this thesis, I aimed at extending the principle of amyloid amplifica-
tion to ↵-synuclein. ↵-Synuclein has been shown to self-propagate in a prion-like
fashion (Luk et al., 2012b; Masuda-Suzukake et al., 2013). This property can be
exploited to amplify ↵-synuclein aggregates in a template-catalysed manner. The
main aim was to establish conditions for the specific amplification of low amounts
of ↵-synuclein propagons, and to investigate possibilities to detect ↵-synuclein ag-
gregates in patient blood samples. Furthermore, the assay was used to investigate
several decontamination agents for their potential to inactivate the propagation
properties of ↵-synuclein aggregates.
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2Digital Insulin Amyloid
Amplification Assay
2.1 Introduction
Biochemical assays for the sensitive detection of protein aggregates are crucial
for basic research and diagnostics. The detection of minute quantities of amyloid
aggregates enables the identification of early steps in the aggregation cascade,
which is instrumental to prevent further propagation of the aggregation reaction. In
this chapter I describe the development of a digital amyloid quantification assay
(d-AQuA) for the detection of single amyloid propagons. The assay combines the self-
propagation properties of amyloid fibrils with the power of digital droplet microfluidics,
which enables the precise quantification of amyloid propagons at low concentrations.
Parts of this chapter are reproduced or quoted verbatim from the following article published by Analytical
Chemistry on November 21, 2017:
Absolute Quantification of Amyloid Propagons by Digital Microfluidics
Manuela Pfammatter, Maria Andreasen, Georg Meisl, Christopher G. Taylor, Jozef Adamcik, Sreenath
Bolisetty, Antoni Sanchez-Ferrer, David Klenerman, Christopher M. Dobson, Ra aele Mezzenga,
Tuomas P. J. Knowles, Adriano Aguzzi, and Simone Hornemann
doi: 10.1021/acs.analchem.7b03279, https://pubs.acs.org/doi/10.1021/acs.analchem.7b03279
Further permissions related to the material excerpted should be directed to the American Chemical
Society.
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2.2 Results
2.2.1 Basic Principle of D-AQuA
To address the challenges mentioned above, I established a digital amyloid ampli-
fication assay, d-AQuA. D-AQuA is a digital amyloid amplification assay used to
quantify amyloid propagons, minute amounts of amyloid protein seeds. The assay
exploits the power of digital droplet microfluidics by partitioning amyloid propagons
into discrete droplets (Fig. 2.1, i) prior to template-catalysed amyloid amplification.
Similarly to droplet digital PCR, amplification of limited dilutions of template amyloid
propagons is performed within individual droplets in a highly parallel manner (Fig.
2.1, ii). This provides the data volumes required for digital analysis and absolute
quantification of propagons in the input sample (Fig. 2.1, iii).
Fig. 2.1.: D-AQuA workflow. (i) Samples containing 10-fold serial dilutions of the standard fibril
sample (blue dashes) are mixed with soluble substrate protein and ThT. The mixtures are
partitioned into several thousand pL-droplets using a microfluidic flow-focusing device. (ii)
Microdroplets are collected into glass capillaries for endpoint amplification and detection by
ThT fluorescence (green). (iii) ThT-positive droplets are counted and the absolute number
of propagons in the standard fibril sample is quantified by Poisson statistics. Reprinted with
permission from Pfammatter et al., 2017.
To generate uniform droplet compartments for highly parallel amplification of single
propagons, a microfluidic chip with flow focusing geometry is used (Fig. 2.2a).
Both oil phase and analyte are floated through the flow focusing junction to form
water-in-oil emulsion droplets at kilohertz frequency (Fig. 2.2a-c). Stable droplets
encapsulating soluble substrate protein, Thioflavin T and serial 10-fold dilutions of
32 Chapter 2 Digital Insulin Amyloid Amplification Assay
propagon-containing input sample are generated. The droplets are collected into
glass capillaries (Fig. 2.2d), and the capillaries are sealed and aligned on a glass
slide (Fig. 2.2e). The glass slide with the capillaries is covered with a hotplate
heated to 65  C to initiate the amplification reaction and mounted on an automated
motorised stage of a fluorescent laser microscope for imaging.
Fig. 2.2.: Experimental setup of d-AQuA. (a) Design of the microfluidic flow focusing device for droplet
generation with oil and sample inlets as well as outlet labelled. (b) Injection of oil and sample
phase. (c) Flow rates are precisely controlled with a syringe pump to form microdroplets
at the flow focusing junction. (d) Droplet collection into glass capillaries. (e) Assembly of
capillaries containing droplets with di erent fibril dilutions. (f) Schematic illustration of the
laser setup used for monitoring the fluorescence intensity of the microdroplets. Reprinted
with permission from Pfammatter et al., 2017.
Template-catalysed amplification of propagons leads to the formation of large amy-
loid aggregates specifically in propagon-encapsulating droplets. Depending on the
dilution of the input sample, a certain fraction of droplets contains propagons, which
are amplified to large aggregates. No amplification takes place in the droplets that
do not contain propagons. At the endpoint, droplets containing amplified aggregates
are detected by their positive ThT fluorescence signals. The number of positive
and negative droplets at every dilution factor is counted. The Poisson distribution
model is applied to determine the absolute number of propagons in the input sample.
The high number of parallel reactions enables a digital interpretation of the data
and allows for a reliable measurement of propagon numbers with high accuracy.
(Pfammatter et al., 2017)
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2.2.2 Insulin Standard Fibril Sample
For the development and validation of d-AQuA, I used human insulin as a model
system. Insulin readily forms amyloid aggregates through mechanistic pathways
analogous to the fibrillation of disease-related amyloidogenic proteins (Jiménez
et al., 2002), and is therefore widely used as an experimental model to study amyloid
formation (Nettleton et al., 2000; Bouchard et al., 2000; Ivanova et al., 2009). I gen-
erated a standard sample of preformed insulin fibrils with reproducible propagation
properties, which was used to establish and validate the d-AQuA method.
Insulin fibrils were reconstituted in vitro by incubating human insulin at a concen-
tration of 1 mM in hydrochloric acid (HCl, pH 2.0) at 65  C and agitation at 600
rpm for 72 h. Residual monomeric protein was removed by intensive washing with
HCl (pH 2.0) (Nilsson and Dobson, 2003). The remaining fibrils were lyophilised
and stored at -20  C. Before usage, fibrils were diluted to a concentration of 400
µM (monomer equivalents) to yield the standard fibril sample. In collaboration with
Ra aele Mezzenga and coworkers (Laboratory of Food and Soft Materials, ETH
Zurich) morphological and biophysical characteristics as well as self-propagation ac-
tivity of the standard fibril sample were analysed (Fig. 2.3). Dynamic light scattering
(DLS) measurements showed that the fibrils have a mean hydrodynamic radius of
85 nm (Fig. 2.3a). Furthermore, both Fourier transform infrared (FTIR) and circular
dichroism (CD) spectra indicated a high  -sheet content (about 86%), which is char-
acteristic of amyloid fibrils (Bouchard et al., 2000; Nelson et al., 2005) (Fig. 2.3b,c).
To assess the propagation activity of the sample, the kinetics of fibril formation by
monomeric insulin in the presence of preformed fibrils from the standard sample
were monitored by optical density at OD370nm (Fig. 2.3d). Increasing concentrations
of preformed fibrils (1, 2 and 5% of total protein concentration) were found to shorten
the lag phase of the aggregation reaction gradually (Fig. 2.3e), as expected for
a nucleated self-assembly process. These results indicate that the standard fibril
sample exhibits the typical biophysical characteristics of amyloid fibrils. (Pfammatter
et al., 2017)
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Fig. 2.3.: Characterisation of the standard fibril sample. The standard fibril sample was characterised
by DLS (a), FTIR spectroscopy (b, shown are the whole spectrum as a solid line and its
deconvoluted peaks as dashed lines), far-UV CD spectroscopy (c) and the self-propagation
activity assay (d). Reprinted with permission from Pfammatter et al., 2017.
2.2.3 Development of D-AQuA
Next, I established the experimental conditions for d-AQuA. 400 µM insulin in HCl
(pH 2.0), 0.1 M guanidinium chloride (GdmCl) and 40 µM ThT were encapsulated
inside microdroplets together with serial 10-fold dilutions ranging from 102 to 108 of
the standard fibril sample (in monomer equivalents). I found that the use of a high
concentration of the substrate and the addition of low amounts of GdmCl, which
accelerates aggregation by inducing partial unfolding of the monomeric species
(Ahmad et al., 2003), were important for e cient amplification. Droplets with di erent
dilutions of preformed fibrils were collected in separate capillaries, mounted on a
microscope slide and heated to 65  C to accelerate the growth and proliferation
of the propagons. Fluorescence images were taken every 15 min to follow the
amplification process in the individual droplets over 24 h (Fig. 2.4a,b). For the
absolute quantification of the number of propagons, I analysed between 500 and
1400 droplets per dilution and digitised the readout by grouping the fluorescence
endpoint signals into positive and negative outcomes by thresholding (see Materials
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and Methods for details). A Poisson distribution was fitted to the number of fluo-
rescence positive (i.e. propagon containing) droplets for each dilution factor at the
assay endpoint. The best fits yielded an average number of 2.1· 1011 propagons per
µL (accurate to within a factor of 1.1, n=2) in the standard fibril sample (Fig. 2.4c).
Moreover, under these conditions I obtained a very low average false positive rate
of only ⇠0.4% spontaneously aggregating reactions in a total of about 700 droplets
of the unseeded control. Because of the high level of conformity of the data to the
Poisson distribution model, I concluded that the assay is capable of amplifying single
propagons in pL droplets and allows the precise quantification of absolute numbers
of propagons at low femtomolar concentrations. (Pfammatter et al., 2017)
Fig. 2.4.: D-AQuA for single propagon quantification. (a) Representative fluorescence images of the
capillaries containing microdroplets with 10-fold serial dilutions of the standard fibril sample.
Droplets containing newly formed aggregates appeared as ThT fluorescence positive,
whereas droplets without preformed fibrils were fluorescence negative. U: unseeded control.
(b) Time courses of insulin fibril formation inside microdroplets for di erent fibril dilutions
(coloured; unseeded control in black) monitored by ThT fluorescence. 200 representative
reactions are shown per dilution. (c) Fraction of fluorescence-positive droplets as a function
of the logarithm of the dilution factor. Every data point represents the mean ± SD from two
independent experiments of d-AQuA. A Poisson distribution was fitted to the data (grey line)
to quantify the number of propagons in the standard fibril sample. Reprinted with permission
from Pfammatter et al., 2017.
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2.2.4 Microplate Digital Amyloid Quantification Assay
Microplate-based amyloid amplification assays in 96-well plate formats with an
analogue readout are the current standard assays for detecting amyloid aggregates
in biological samples (Salvadores et al., 2014; Shahnawaz et al., 2017; McGuire
et al., 2016). To enable a direct comparison between the sensitivity of this method
with d-AQuA, I developed an amyloid amplification assay for insulin in a microplate
with a digital readout (Fig. 2.5). As the precision of digital readouts increases with
the number of replicate reactions, I established the assay in a 384-well format. I also
adapted the experimental conditions to account for the higher volumes and larger
surface areas used in the microplate assay. A range of experimental parameters
including substrate protein concentration, temperature, shaking cycles, pH value,
bu er conditions and additives were systematically screened and optimised for best
assay performance. Especially crucial was the addition of  -mannitol, which has
recently been reported to suppress spontaneous nucleation of insulin by stabilisation
of the monomer, while enhancing the growth rate of existing fibrils (Saha et al., 2016).
Formic acid (HCOOH) at pH 3.0 was chosen as the solvent, because of its reported
ability to reduce spontaneous aggregation of monomeric insulin (Brange et al.,
1997). Finally, I identified a concentration of 2 µM soluble substrate protein in 0.75
M  -mannitol, 1 M GdmCl, 10 µM ThT, HCOOH (pH 3.0) with cyclic agitation (1 min
at 300 rpm, 2 min quiescent) at 30  C as optimal assay conditions. These conditions
resulted in an e cient reduction of spontaneous aggregation to a false positive rate
of 1–2% in 384 replicates over the course of the experiment (24 h), while yielding
highly reproducible aggregation kinetics of the propagon-catalysed reactions (Fig.
2.5a).
For digital quantification of the propagon number in our standard fibril sample, I
again performed serial 10-fold dilutions of the standard fibril sample (104- to 1015-fold
dilutions in monomer equivalents) using 16 replicates per dilution. The aggregation
time course was monitored by real-time ThT fluorescence over 24 h (Fig. 2.5a). At
low dilutions (104- to 109-fold), I observed lag times of approximately 8 h, which
gradually increased with higher dilutions of preformed fibrils. Endpoint fluorescence
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Fig. 2.5.: Microplate amyloid amplification assay. (a) Real-time ThT fluorescence time courses of
insulin fibril formation with 10-fold serial dilutions from 104 to 1015 of the standard fibril
sample on a microplate (coloured; unseeded controls in black). All reactions and the control
reaction were performed in 16 technical replicates. (b) Fluorescence endpoint signals at
di erent fibril dilution factors (coloured; unseeded controls in black, U). The grey dashed
line shows the threshold (x¯0 + 5 0) used for the positive/negative scoring of the signals. (c)
Fraction of positive wells as a function of the logarithm of the dilution factor. Data represent
the mean ± SD from three independent experiments. A Poisson distribution was fitted to the
data (grey line) to quantify the number of propagons in the standard fibril sample. Reprinted
with permission from Pfammatter et al., 2017.
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signals of reactions with low dilution factors ( 109-fold) of preformed fibrils were
all positive, whereas at higher dilutions only fractions of the replicate reactions
appeared positive (14, 6 and 1 out of 16 replicates for 1010-, 1011- and 1012-fold
dilutions, respectively). All reactions at dilution factors   1013-fold, as well as the
control (without preformed fibrils) were scored negative (Fig. 2.5b). The fraction of
positive signals was correlated with the dilution factors, and a Poisson distribution
was fitted to the data (Fig. 2.5c). The best fit yielded an average number of 1.4 ·
109 propagons µL 1 (accurate to within a factor of 1.2, n=3) in the standard fibril
sample. These data show that the microplate assay (1.4 · 109 propagons µL 1) is
also capable of detecting individual propagons. However, compared to d-AQuA (2.1
· 1011 propagons µL 1) two orders of magnitude less propagons were detected with
the microplate assay.
The detection of a lower number of active propagonsmight be due to a loss of fibrils to
various solid surfaces during the extensive pipetting steps or due to their adherence
to the microplate surface. The absence of solid contact surfaces in the microdroplets
or the small droplet sizes, associated with higher e ective concentrations (Guo et
al., 2012), might result in a higher number of e ective propagons. High losses of
propagons, however, significantly impair the sensitivity and reproducibility of the
microplate assay. Compared to the microplate assay, d-AQuA also exhibited a
greatly reduced average false positive rate of unspecific amplification reactions in
the unseeded control (⇠0.4% compared to 1-2%) and decreased assay time (⇠8 h
compared to 24 h). (Pfammatter et al., 2017)
2.2.5 Validation With Quantitative Atomic Force Microscopy
To complement the data obtained by d-AQuA with an alternative method, I used
atomic force microscopy (AFM), measured in collaboration with Ra aele Mezzenga
and coworkers (Laboratory of Food and Soft Materials, ETH Zurich). This allowed
me to estimate the dimensions and physical number of fibrillar aggregates present in
the standard fibril sample (Fig. 2.6a). The average contour length of the fibrils was
(50± 35) nm (Fig. 2.6b) and the height was (5.3± 1.7) nm (Fig. 2.6c). I used these
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dimensions and mass conservation to calculate the physical number of fibrils per unit
volume of the standard fibril sample (see ’Fibril Quantification by AFM’ in Materials
and Methods section for details). The calculations yielded an average number of
1.1 · 1012 µL 1 fibrils. This number is very similar (less than an order of magnitude,
i.e. within a factor of ⇠5) to the number of propagons determined by d-AQuA (2.1
· 1011 propagons µL 1). A possible explanation for the small di erence between
these numbers might be that not all fibrillar aggregates detected by AFM also act
as active propagons in d-AQuA. I therefore concluded that the active propagons
detected by d-AQuA are identical to a fraction of morphologically defined fibrillar
aggregates. (Pfammatter et al., 2017)
Fig. 2.6.: Quantitative AFM measurements. (a) AFM height image of preformed insulin fibrils. (b)
Histogram of the fibril contour length distribution of preformed insulin fibrils. (c) Histogram of
the average height distribution of the preformed insulin fibrils. Data were fitted to a Gaussian
distribution (solid line) to obtain the mean ± SD of the contour length and the fibril heights.
Reprinted with permission from Pfammatter et al., 2017.
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2.3 Discussion and Outlook
In this chapter, I described d-AQuA, a digital amyloid amplification assay in which
the power of digital microfluidics was exploited for the sensitive detection and quan-
tification of amyloid propagons. In d-AQuA, individual amplification reactions were
encapsulated inside microdroplets and amplified in a template-catalysed way. The
encapsulation allowed the parallel amplification of thousands of reactions in pL
volumes for highly accurate and precise digital data analysis. The presented results
showed that d-AQuA enables the measurement of the activity of single propagons
and the digital quantification of the absolute number of propagons present in a
sample. With the capability to detect single propagons, the assay reached the
ultimate sensitivity limit of detection.
Compared to the microplate assay, which also reached the ultimate level of sensi-
tivity, d-AQuA was shown to be the more rapid and precise method and to have a
higher recovery rate of low-abundance propagons. The microfluidic assay o ers
several important advantages over the most commonly used amyloid amplification
assays, PMCA (Saborio et al., 2001) and RT-QuIC (Wilham et al., 2010; Orru et al.,
2012). First, the large numbers of replicate measurements in d-AQuA (up to 1400
compared to typically 3 to 8 in PMCA (Saborio et al., 2001) and RT-QuIC (Wilham et
al., 2010; Orru et al., 2012)) yielded highly precise data sets through more powerful
statistical analysis of the data. D-AQuA enables the detection of single propagons
and absolute propagon quantification, whereas in PMCA and RT-QuIC, propagons
were typically quantified either in gram or mol or given as amyloid seeding activity
or tissue dilutions (Saborio et al., 2001; Wilham et al., 2010; Orru et al., 2012).
Compared to PMCA (Saborio et al., 2001), d-AQuA also provides a simpler and
faster readout by using ThT fluorescence instead of detection by immunoblotting. In
experiments described in this study, d-AQuA also required a significantly decreased
assay time (⇠8 h compared to typically 1-3 days in PMCA (Saborio et al., 2001;
Orru et al., 2012) and RT-QuIC (Orru et al., 2012)), reduced labor-intensive and
time-consuming pipetting steps and associated errors. Moreover, the use of pL-
droplets instead of µL-volumes significantly reduced the consumption of reagents
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and, in particular, of the analyte. This is crucial, when precious clinical samples
with a low concentration of propagons need to be analysed. Hence, d-AQuA o ers
a major improvement over the microplate assays in determining exact numbers
of propagons, a result that is of major importance in the context of ultrasensitive
detection and precise quantification of the number of low-abundance propagons in
a given sample. (Pfammatter et al., 2017)
The most important innovation of d-AQuA is the precise, absolute quantification
of amyloid propagons without the need of a standard curve. The idea to quantify
amyloid propagons based on their seeding or propagation activity has already been
described for the PMCA assay (Chen et al., 2010) and for the RT-QuIC assay (Wil-
ham et al., 2010; Shi et al., 2013; Henderson et al., 2015; Takatsuki et al., 2015).
In these studies, the amounts of PrPSc seeds was correlated either to the number
of PMCA rounds required for the immunodetection of amplified PrPSc (Chen et al.,
2010), to the seeding dose (SD50, the dilution at with 50% of RT-QuIC reactions are
positive (Wilham et al., 2010)), or to the lag time of the conversion reaction (Shi et al.,
2013) for quantification. However, in all previous studies, PrPSc has been quantified
by interpolation of the unknown sample on a standard calibration curve derived from
a reference sample with known amounts of PrPSc. The absolute PrPSc quantities
in the reference sample were determined by independent methodologies such as
immunoassays. By contrast, d-AQuA enables absolute quantification directly from
the number of propagation-positive replicates without the need for a standard curve.
Individual propagons are counted directly, which greatly increases the accuracy of
quantification.
The sensitive detection and absolute quantification of propagating amyloid aggre-
gates o er the possibility for multiple applications. The detection and quantification
of small traces of insulin propagons, which are not detectable with conventional
analytical methods, might be relevant to the pharmaceutical production of insulin.
Recombinantly produced insulin for the treatment of diabetes patients was shown to
be prone to aggregation (Waugh, 1944; Waugh, 1946), which can cause problems in
drug formulation, stability and pharmacokinetics (Brange et al., 1997). Aggregation
of pharmaceutical proteins can a ect product quality through impeding deliverability
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and absorption or through eliciting undesired immunogenicity in patients (Roberts,
2014). Identification of early protein aggregation in pharmaceutical products is in-
evitable to guarantee product quality and stability. D-AQuA could serve as a quality
control assay for pharmaceutical insulin products. The detection of early aggregated
states during di erent stages of the manufacturing process would help to optimise
manufacturing and to prevent biotechnical and biomedical problems arising from
insulin aggregation. As a result, product quality and stability could be improved.
Finally, d-AQuA represents a proof-of-concept assay for amyloid amplification, which
could be adapted to a range of di erent amyloidogenic protein systems. The assay
holds great potential for ultrasensitive and rapid diagnosis of protein aggregation
diseases such as prion diseases, ↵-synucleinopathies, and Alzheimer’s disease.
Through the detection of minimal quantities of early pathological aggregates, the
method might be sensitive enough for preclinical diagnosis. In particular, a small-
volume, single-use disposable chip with the ability to diagnose protein aggregation
diseases accurately from body fluids in a point-of-care manner holds great promise
for novel automated diagnostic approaches.
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2.4 Materials and Methods
2.4.1 Materials
Human insulin was purchased from Sigma-Aldrich (SAFC Biosciences) and used
without further purification. All chemicals unless otherwise specified were purchased
from Sigma-Aldrich.
2.4.2 Standard Fibril Sample Preparation
Fibrils were assembled in vitro by incubating 1 mM monomeric human insulin in
a 10 mM HCl water solution at pH 2.0 (HCl, pH 2.0) at 65  C and agitation at 600
rpm for 72 h. Residual monomeric species were removed by intense washing with
HCl (pH 2.0) using Amicon centrifugal filters with a molecular weight cut-o  of 100
kDa (Nilsson and Dobson, 2003). Fibrils were lyophilised and stored at -20  C until
usage. The sample was diluted to a concentration of 400 µM (monomer equivalents)
to yield the standard fibril sample.
2.4.3 Atomic Force Microscopy
A droplet of 20 µL of insulin fibril solution (1 µM in HCl, pH 2.0) was deposited on
freshly cleaved mica substrate, incubated for 2 min at room temperature, rinsed
with deionised water to remove unbound fibrils, and dried with compressed air
flow. The samples were scanned on a MultiMode VIII Scanning Probe Microscope
(Bruker) covered with an acoustic hood to minimise vibrational noise. The AFM
was operated in tapping mode under ambient conditions using commercial silicon
nitride cantilevers. The AFM images were acquired with a scan rate of 0.1 Hz and a
resolution of 5120 x 5120 pixels per image. All images were flattened to remove
background curvature using the Bruker Nanoscope 8.10 software. No further image
processing was carried out. The contour lengths and the average height distributions
were extracted from >95,000 individually traced fibrils using FiberApp (Usov and
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Mezzenga, 2015), an open-source tracking and analysis software written in Matlab
(The MathWorks, USA).
2.4.4 Dynamic Light Scattering
DLS spectra of a 100 µM insulin fibril solution in HCl (pH 2.0) were recorded us-
ing a 3D cross-correlation dynamic light scattering spectrometer (LS instruments)
equipped with a He-Ne-Laser emitting polarised light at a wavelength of 632.8 nm.
Dynamic light scattering measurements were performed at room temperature at a
fixed scattering angle of 90 . The spectrum represents the average of three inde-
pendent measurements of 600 s each. Time correlation functions of the scattered
intensity were analysed using the CONTIN analysis algorithm (Provencher, 1982).
2.4.5 Fourier Transform Infrared Spectroscopy
FTIR spectra of lyophilised insulin fibrils were obtained by using a Varian 640
FTIR spectrometer (Varian Inc.) equipped with a Specac Diamond ATR Golden
Gate single attenuated total reflection (ATR) system. Samples were scanned at
room temperature over the range of 4000 to 600 cm 1 with a resolution of 2 cm 1,
averaged over 64 scans, and baseline corrected. The amide region was normalised,
resolved by second-derivative analysis, and peak deconvoluted using Igor Pro
6.3.4.1 software.
2.4.6 Far-UV Circular Dichroism Spectroscopy
CD spectra were obtained on a Jasco J-815 spectropolarimeter (Jasco Inc.) at 25
 C using an insulin concentration of 20 µM in HCl (pH 2.0). Far-UV CD spectra were
recorded in a 0.1 cm precision quartz cuvette (Hellma) from 200 to 260 nm with a
data pitch of 0.2 nm, a bandwidth of 2 nm and a scanning speed of 20 nm min 1.
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Spectra were background subtracted and averaged over 10 scans. The molar mean
residue ellipticity ✓mrw was calculated as
✓mrw =
✓
d · c · naa (2.1)
where ✓ is the measured ellipticity, d the thickness of the cuvette, c the concentration
and naa the number of residues of insulin.
2.4.7 Self-Propagation Activity Assay
The self-propagation activity of the preformed insulin fibrils was assessed in a
seeded aggregation experiment. 400 µM monomeric insulin was mixed with 0, 1, 2
and 5% (related to the monomer concentration) preformed fibrils and incubated in
HCl (pH 2.0) at 45  C and 300 rpm continuous agitation in 96-well polystyrene mi-
croplates (Corning, Prod.No. 3880). The aggregation time course was monitored by
following the absorbance at 370 nm using a Spectramax Paradigm microplate reader
(Molecular Devices). Triplicate measurements of all conditions were performed and
averaged to calculate mean and standard deviations of the lag phases.
2.4.8 Microdroplet Device Fabrication
Microfluidic flow focusing devices (Fig. 2.2a) were fabricated using standard soft-
lithography techniques (McDonald et al., 2000). Briefly, the device design was
patterned on a silicon wafer using SU-8 negative photoresist (MicroChem) to produce
a negative mold. Microfluidic channels were cast into poly(dimethylsiloxane) (PDMS;
Dow Corning Sylgard 184 Silicone Elastomer) on the silicon mold, and the PDMS
stamp was cured at 65  C for 150 min before peeling o  the mold. Channel inlets
and outlets were punched into the PDMS stamp before oxygen plasma bonding
it to a glass slide to seal the channels. To make channel walls hydrophobic, the
device was flushed with the water repellent agent Aquapel (PPG Industries) for 30
min before washing with isopropanol and then blow-dried with a nitrogen stream.
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2.4.9 D-AQuA Assay
Lyophilised insulin was dissolved in HCl (pH 2.0) at a concentration of 6 mgmL 1 and
filtered (50 kDa Amicon centrifugal filters; Millipore UFC505096) to remove higher
molecular weight species. The protein was dissolved to a final assay concentration
of 400 µM in HCl (pH 2.0) containing 0.1 M GdmCl and 40 µM Thioflavin T (ThT).
Serial 10-fold dilutions of the standard fibril sample were prepared in HCl (pH 2.0)
and added to the reaction mixture immediately before encapsulating the mixture into
microdroplets. Negative controls were incubated with the same volume of HCl (pH
2.0) instead of fibrils. Amplification reactions were encapsulated into water-in-oil
emulsions using a microfluidic device with flow focusing geometry. The sample
containing monomeric substrate, fibrils and ThT was injected into the middle inlet
on the chip at a flow rate of 200 µL h 1. The carrier oil phase made of fluorinated
FC-40 (Sigma) with 4% (w/v) triblock co-polymer (ABA) surfactant (where A is
a perfluorinated poly(propylene oxide) block and B a poly(ethylene oxide) block,
synthesised as previously described (Holtze et al., 2008)) was injected into the
outer inlet at a flow rate of 300 µL h 1 to generate droplets with a radius of ⇠25
µm (volume ⇠65 pL). Flow rates were controlled with a Cetoni neMESYS syringe
pump (Cetoni GmbH). Between 500 and 1400 replicate droplets were collected per
dilution at the outlet into Rectangular Borosilicate capillaries (CM Scientific), and
the capillaries were sealed with wax plugs to prevent sample evaporation. Before
imaging the capillaries containing samples at di erent fibril dilutions, capillaries
were aligned on a glass slide for amplification and imaging. The aligned capillaries
were placed on the automated motorised stage of a custom-built epifluorescence
laser microscope (Fig. 2.2f) and covered with a hotplate heated to 65  C to induce
amplification. To track aggregate formation inside the droplets, fluorescent images
were acquired every 15 min for approximately 24 h using laser excitation at 445 nm
(diode laser (MLD445, Cobolt)). Individual droplets were identified manually, and
the average intensity of the droplet area was extracted for all frames. The brightness
of the images of the 102 capillary in Figure 2.4a was adjusted to account for minor
di erences in brightness arising from imaging on di erent frames of the automated
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stage laser. Fluorescent traces in Figure 2.4b were considered complete once the
plateau region was obtained.
2.4.10 Microplate Amyloid Amplification Assay
Lyophilised insulin was dissolved in HCOOH (pH 3.0) at a concentration of 6 mg
mL 1 and filtered using 50 kDa Amicon Ultra centrifugal filters (Millipore, Prod. No.
UFC505096). The protein was dissolved to a final concentration of 2 µM in 0.75
M  -mannitol, 1 M GdmCl, 10 µM ThT, HCOOH (pH 3.0) in a reaction volume of
28.5 µL per well. To each reaction either 1.5 µL of serial 10-fold dilutions from 104
to 1015 of the standard fibril sample (dissolved in HCOOH, pH 3.0) or HCOOH (pH
3.0, negative control) was added. Each dilution and the control were performed in
sixteen technical replicates on black 384-well polystyrene microplates (Corning, Prod.
No. 3540) covered with sealing tape (Sarstedt, Prod. No. 95.1999). Microplates
were incubated at a constant temperature of 30  C with cyclic agitation (1 min
at 300 rpm followed by 2 min quiescent) on a SpectraMax Paradigm microplate
reader (Molecular Devices). To monitor the aggregation kinetics, ThT fluorescence
was measured at 482 nm following excitation at 440 nm every 3 min using bottom
read. The error of the assay was calculated from three independent replicate
measurements of the microplate assay.
2.4.11 Digital Data Analysis
To digitise the assay readout for absolute propagon quantification, fluorescence
endpoint values of the amplification reactions were transformed into positive and
negative signals by thresholding. For the microplate assay, the threshold was set to
five standard deviations above the mean of the unseeded negative control reactions
(x¯0 + 5 0). Any signal above the threshold was regarded as positive signal. For
d-AQuA, droplets which showed positive ThT fluorescence at the endpoint were
scored positive. The fraction of positive droplets at every dilution was then calculated
from the number of positive droplets and the total number of droplets counted in
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the corresponding brightfield images. The absolute number of propagons in both
assays was calculated using the Poisson distribution model. The probability of
finding k propagons in a reaction compartment if the average number of propagons
per reaction compartment is  , is described by the Poisson distribution
P (X = k) =
 ke  
k!
(2.2)
The probability of having one or more propagons per reaction compartment (the
probability of a positive signal) is given by
P (X > 0) = 1  P (X = 0) = 1  e   (2.3)
where P (X = 0) is the probability of not having any propagons in the reaction
compartment (the probability of a negative signal). For the di erent dilution factors d,
the probability of having one or more propagons per compartment can be described
as
Pd(X > 0) = 1  e  /d (2.4)
where   is the average number of propagons in the original sample and d is the
dilution factor. The fraction of positive signals can be related to the dilution factors
using equation 2.4, and therefore the absolute number of propagons in the original
sample   can be calculated. All data analysis was carried out using Matlab (The
MathWorks, USA).
2.4.12 Fibril Quantification by AFM
The number of fibrils per unit volume of the standard fibril sample was estimated
from AFM length distribution and mass conservation. The distribution of fibrils Ni(L)
as a function of the contour length measured by AFM is shown in Figure 2.6b. This
distribution is essentially the same distribution of fibrils per unit volume, di ering by
a mere normalisation constant ↵, so that the distribution of fibrils per unit volume is
simply ↵Ni(L). The constant ↵ can be obtained from the total mass per unit volume,
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which is obtained from the initial molar concentration of monomer cm, i.e. cmMW .
Therefore, by mass conservation this results in
X
↵Ni(L) · Li⇡r2⇢ = cmMW, (2.5)
where ⇢ is the density of the monomer and the fibril, that are assumed here to be
identical. This then gives ↵ = cmMWPNi(L)·Li⇡r2⇢ , since all the terms on the right hand
are known.
The total number of fibrils per unit volume, NfV , is then
Nf
V
=
X
↵Ni(L) = ↵
X
Ni(L) =
cmMW
⇡r2⇢
P
Ni(L) · Li
X
Ni(L), (2.6)
where both
P
Ni(L) · Li and Ni(L) are known from the distribution of fibrils as a
function of the contour length in Figure 2.6b.
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3Real-Time Quaking-Induced
Conversion Assay
3.1 Introduction
The real-time quaking-induced conversion (RT-QuIC) assay is a sensitive assay for
the detection of the misfolded form of the prion protein (PrPSc). It is based on the
self-propagation properties of PrPSc, which stimulates the conversion of PrPC into
PrPSc. Monomeric full-length hamster prion protein (HaPrP23 231) as a substrate
of the amplification reaction is converted into large aggregates through PrPSc. The
PrPSc aggregates are amplified through cyclic shaking, which fragments the aggre-
gates into smaller propagons and catalyses the conversion of monomeric PrP.
In this thesis I describe the establishment and di erent applications of the RT-QuIC
assay to detect PrPSc in human brain tissues and cerebrospinal fluid (CSF) for CJD
diagnostics, in murine cerebellar organotypic slice cultures, and on the metal surface
of PrPSc-coated steel beads.
Parts of this chapter (section on RT-QuIC with cerebellar organotypic cultured slices) are reproduced
or quoted verbatim from the following article published by PLoS One on September 29, 2016:
Neurotoxic Antibodies against the Prion Protein Do Not Trigger Prion Replication
Karl Frontzek, Manuela Pfammatter, Silvia Sorce, Assunta Senatore, Petra Schwarz, Rita Moos, Katrin
Frauenknecht, Simone Hornemann, Adriano Aguzzi
doi: 10.1371/journal.pone.0163601, https://doi.org/10.1371/journal.pone.0163601
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3.2 Results
3.2.1 Expression and Purification of Hamster Prion Protein
A prerequisite for the RT-QuIC assay is the high purity of the substrate protein needed
for conversion. Towards this goal a gene block encoding the hamster (Mesocricetus
auratus) prion protein gene was cloned into the pRSET A expression vector using
the NdeI and EcoRI restriction sites. The protein was overexpressed in E. coli, and
the purification protocol was optimised for high production yields. Briefly, the protein
was isolated from inclusion bodies and purified by Ni2+-nitriloacetic acid (Ni-NTA)
a nity chromatography (Fig. 3.1a, see Materials and Methods for more details).
The identity of the purified protein was confirmed by electrospray ionisation mass
spectrometry (ESI-MS; Fig. 3.1b). The peak at m/z 23,102 corresponded to the
molecular mass of HaPrP23 231 (expected MW: 22,973 Da, + 131 Da for methionine,
- 2 Da oxidation of cysteines = 23,102 Da). The purity of the sample was analysed
by SDS-PAGE (Fig. 3.1c). The average purification yield was 50 mg of highly pure
HaPrP23 231 per litre of bacterial culture.
3.2.2 Diagnostic RT-QuIC
The highly specific and sensitive amplification of PrPSc makes the RT-QuIC a useful
tool for the reliable and accurate diagnosis of Creutzfeldt-Jakob disease (CJD). The
methodology was adapted to test patient samples such as brain tissue or CSF for
the presence of PrPSc. In the CSF RT-QuIC small amounts of PrPSc in patient CSF
convert monomeric PrP into detectable PrPSc aggregates. It therefore allows the
discrimination of CSF samples from sCJD patients containing pathological PrPSc
aggregates from CSF samples from healthy donors.
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Fig. 3.1.: Production and characterisation of HaPrP23 231. (a) Elution profile of Ni-NTA a nity purifi-
cation. (b) ESI-MS of purified HaPrP23 231 (expected molecular weight 22,973 Da + 131 Da
- 2 Da = 23,102 Da). (c) SDS-PAGE purity analysis of HaPrP23 231. The gel was stained
with Coomassie protein stain (InstantBlue, Expedeon).
Ring Trial Validation
The RT-QuIC was initially validated with human CSF samples provided by the
National CJD Research & Surveillance Unit (NCJDRSU), Edinburgh, UK. Similar as
in the international ring trial conducted by the NCJDRSU previously, ten blinded CSF
samples were analysed by RT-QuIC (Fig. 3.2) using experimental and instrumental
parameters as published by the NCJDRSU (McGuire et al., 2016). All samples were
analysed using both the substrate HaPrP23 231 provided by the NCJDRSU as well
as with in-house produced HaPrP23 231. CSF samples with 3 or 4 positive RT-QuIC
responses out of 4 replicate reactions were diagnosed as RT-QuIC positive. Out of
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Fig. 3.2.: RT-QuIC analysis of human CSF samples from the NCJDRSU ring trial. Real-time ThT
fluorescence time courses of RT-QuIC reactions seeded with of human CSF samples
provided by the NCJDRSU. All reactions were seeded with 30 µL of CSF and performed in
quadruplicate.
ten blinded samples, five were found to be RT-QuIC positive (EDI_1, 2, 5, 6, 8) and
five were RT-QuIC negative (EDI_3, 4, 7, 9, 10). All samples were unambiguously
positive (4/4 replicates positive) or negative (0/4 replicates positive). The RT-QuIC
results were compared to the clinical diagnoses provided by the NCJDRSU (Tab. 3.1).
All samples coincided with the corresponding clinical diagnosis. This validation
experiment showed that the RT-QuIC assay was successfully transferred to our
laboratory, and that the method can be used to accurately and reliably diagnose
sCJD from CSF samples.
Patient ID Gender Age Diagnosis RT-QuIC Result
EDI_1 f 67 probable sCJD positive
EDI_2 f 70 probable sCJD positive
EDI_3 m 73 not CJD negative
EDI_4 m 82 not CJD negative
EDI_5 m 75 probable sCJD positive
EDI_6 m 68 confirmed sCJD positive
EDI_7 m 72 not CJD negative
EDI_8 f 64 probable sCJD positive
EDI_9 f 44 not CJD negative
EDI_10 m 61 not CJD negative
Tab. 3.1.: Demographic data, clinical diagnosis and results of the RT-QuIC analysis of CSF samples
from ring trial. Samples were provided by the National CJD Research & Surveillance Unit,
Edinburgh, United Kingdom.
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sCJD Diagnostics
The CSF 14-3-3 protein is a surrogate marker for neuronal degeneration. Although
widely used for the premortem clinical diagnosis of CJD, it is not entirely specific
(Collins et al., 2000; Zerr et al., 2009). To complement this lack in specificity, the
CSF RT-QuIC was implemented as a tool for diagnosing CJD. The assay was
further validated by testing autopsy-confirmed brain tissue and CSF samples of
our brain biobank (Fig. 3.3). All RT-QuIC test results were consistent with the
neuropathological, definite diagnoses, and the CSF RT-QuIC assay has since been
included in the diagnosis of suspected CJD cases.
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Fig. 3.3.: Example results of diagnostic CSF RT-QuIC. (a) Plate controls included on every RT-QuIC
experiment. Unseeded RT-QuIC reaction (black), brain homogenate of a patient with CJD
diagnosis excluded (green), brain homogenate of a patient with confirmed CJD (red). (b)
RT-QuIC results of a CJD-negative patient (upper panel, green) and a CJD-positive patient
(lower panel, red). All CSF samples were tested in quadruplicate using three di erent
volumes (30, 15, 7.5 µL) of CSF in the reaction mixture.
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3.2.3 Steel Beads RT-QuIC
Prions are highly resistant to conventional decontamination and sterilisation proce-
dures (Taylor, 2000). Additionally, prions strongly adsorb to stainless steel surfaces
and can transmit infectivity via steel surfaces (Zobeley et al., 1999; Flechsig et al.,
2001). These properties increase the risk of iatrogenic prion transmission from
contaminated surgical stainless steel instruments. To date, there are no e ective
and practical decontamination treatments for surgical steel surfaces. Daniel Heinzer
and colleagues (Institute of Neuropathology, University Hospital Zurich) have been
testing new prion decontaminating formulations developed for the inactivation of
pathological prions on medical instruments in collaboration with Borer Chemie AG
(Zuchwil). Stainless steel beads coated with mouse prions were used to study the
e ect of di erent decontamination formulations on prion infectivity. Daniel Heinzer
and colleagues developed a cell-based prion infectivity assay to assess the decon-
tamination e ciency of the new formulations. In addition, I adapted the RT-QuIC
assay to test propagation activity of steel surface-bound prions inactivated with
decontamination reagents.
Development of a Steel Beads RT-QuIC
Introducing prion-coated steel beads in the RT-QuIC reaction might a ect the con-
version reaction in various ways. The beads might cause false positive aggregation
by introducing shear forces to the system or through the exposure of additional
surfaces. Alternatively, the beads might interfere with the template-catalysed conver-
sion of PrPC into the aggregated prion protein. In a first proof-of-concept experiment,
the e ect of steel beads on the RT-QuIC reaction mixture was studied. Therefore,
Daniel Heinzer and colleagues treated steel beads with 1% non-infectious brain
homogenate (NBH) and 1% prion-infected brain homogenate from the Rocky Moun-
tain Laboratory strain (RML), respectively, and washed them thoroughly with PBS
to remove unbound infectivity. I then added the beads to the RT-QuIC reaction
mixture to investigate their e ect on the conversion (Fig. 3.4). While both untreated
beads as well as NBH-coated beads did not cause any aggregation in the RT-QuIC,
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Fig. 3.4.: Proof-of-concept steel beads RT-QuIC. 20,000 (upper panel) and 2,000 (lower panel)
untreated (black), NBH-coated (green) and RML-coated (red) stainless steel beads were
used as seeds in the RT-QuIC assay. ThT fluorescence was recorded every 15 min over
the course of 90 h. All reactions were performed in quadruplicate.
RML-treated beads were able to seed the conversion of PrPC into PrPSc e ciently.
When seeded with either 20,000 or 2,000 RML-coated steel beads, all four replicate
RT-QuIC reactions showed a significant increase in ThT fluorescence, indicating
the amplification of protein aggregates through seeding. These results led to the
conclusion that introducing steel beads into the RT-QuIC did not interfere with the
conversion reaction.
To optimise the number of beads used per well, I tested di erent bead numbers in
the assay. Between 200,000 and 250 NBH- and RML-coated beads were added
to the RT-QuIC reaction mixture (Fig. 3.5). At bead numbers higher than 50,000
beads, all four replicates of the RT-QuIC reactions seeded with RML-coated beads
showed an increase in ThT fluorescence indicating the seeded conversion of prion
aggregates. At 1,000 and 500 beads, only 2 and 1 replicate reactions, respectively,
were RT-QuIC positive. Seeding with 250 RML-coated steel beads was not e cient,
in that it did not show any positive ThT signal. NBH-coated steel beads did not cause
any seeded conversion. However, at the highest bead number, a false positive RT-
QuIC signal was detected for one out of four replicate reactions. The false positive
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Fig. 3.5.: Steel beads RT-QuIC with di erent numbers of NBH- (upper panel, green) and RML-coated
beads (lower panel, red). Between 200,000 and 250 NBH- and RML-coated beads were
added to the RT-QuIC reaction mixture. ThT fluorescence was recorded every 15 min over
the course of 105 h. All reactions were performed in quadruplicate.
signal was most likely caused by seed-independent aggregation initiated by a strictly
monomer-dependent primary nucleation event. The spontaneous generation of PrP
aggregates through the nucleation of monomeric PrPC might have been catalysed
by the metal surface of the beads as proposed earlier (Edgeworth et al., 2010).
To minimise the risk of false positive ThT signals and thus false positive RT-QuIC
results, the bead number for further RT-QuIC analyses was set to 100,000 and
10,000 beads per well. These bead numbers should be high enough to detect prions
adsorbed to the bead surface, while preventing false positive results provoked by
the beads.
In a next step, the steel beads RT-QuIC was validated using standard protocols
for prion decontamination. 100,000 and 10,000 RML-coated beads treated with
either NaOH (1 M for 2 h at room temperature) or SDS (3% for 10 min at 95  C)
were assessed using the RT-QuIC assay (Fig. 3.6). Bead samples decontaminated
with NaOH failed to seed the RT-QuIC reaction after treatment, which confirms
the prion decontamination e ciency of NaOH. In contrast, samples treated with
SDS showed only partial decontamination. While no positive signal was detected in
the RT-QuIC reactions seeded with 10,000 steel beads, all four replicate reactions
seeded with 100,000 beads were RT-QuIC positive. These results are in agreement
with previously published data (Mori et al., 2016), and thus validate the applicability
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Fig. 3.6.: Validation of steel beads RT-QuIC with standard prion decontamination protocols. 100,000
(upper panel) and 10,000 (lower panel) RML-coated beads were treated with 1 M NaOH for
2 h at room temperature (orange), with 3% SDS for 10 min at 95  C (blue), or with PBS for
10 min at 95  C (purple), and added to the RT-QuIC reaction mixture. ThT fluorescence
was recorded every 15 min over the course of 105 h. All reactions were performed in
quadruplicate.
of the steel beads RT-QuIC for the study of prion decontamination reagents on steel
bead surfaces.
Screening of Prion Decontamination Formulations
In a first test, the decontamination e ciency of seven commercially available prod-
ucts (Tab. 3.2) was assessed using the steel beads RT-QuIC. Therefore, the seeding
activity of RML-coated steel beads treated with the commercial decontamination
formulations was evaluated (Fig. 3.7). Only one of the tested products (PR-7,
ALKAPHARM ALKA 100) e ciently inactivated prions adsorbed to the steel beads,
evident by the complete abolishment of seeding activity in the RT-QuIC. Beads
treated with other products either showed a slight reduction in the seeding activity
as only a fraction of the four replicate reactions showed a positive ThT signal at late
time points (PR-2, PR-4, PR-6) or had no e ect on the RT-QuIC reaction (PR-1,
PR-3, PR-5). This suggests that the majority of the commercially available cleaning
products for prion decontamination show an insu cient prion decontamination ac-
tivity.
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Fig. 3.7.: Steel beads RT-QuIC with prion-coated steel beads inactivated with commercially available
decontamination products. 100,000 RML-coated steel beads were treated with seven
commercially available prion decontaminants for 10 min at 55  C, and added to the RT-QuIC
reaction. Untreated RML (red) and RML treated with NaOH for 2 h at room temperature
(grey) were used as controls. ThT fluorescence was recorded every 15 min over the course
of 105 h. All reactions were performed in quadruplicate.
Product Product ID Manufacturer Concentration
Deconex 28 Alka One-X PR-1 Borer Chemie AG 0.5%
Deconex Prozyme Alka 2.0 PR-2 Borer Chemie AG 0.5%
Deconex Power Zyme PR-3 Borer Chemie AG 0.5%
Neodisher Septoclean PR-4 Dr. Weigert 0.5%
Deconex TWIN PH10 & Zyme PR-5 Borer Chemie AG 0.3 & 0.2%
ACTANIOS WD PR-6 Laboratoires ANIOS 0.5%
ALKAPHARM ALKA 100 PR-7 ALKAPHARM 0.5%
Tab. 3.2.: Commercial prion decontamination products, product ID, manufacturer and concentrations.
All products were provided by Borer Chemie AG.
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Fig. 3.8.: Example RT-QuIC screening of 24 newly developed prion decontamination formulations.
100,000 RML-coated steel beads were treated with formulations for 10 min at 55  C, and
their e ciency was assessed using RT-QuIC. ThT fluorescence was recorded every 15 min
over the course of 105 h. All reactions were performed in quadruplicate. The formulations
were synthesised by Borer Chemie AG (Zuchwil).
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In a collaborative project, Daniel Heinzer and Borer Chemie AG aimed at developing
a practically applicable product for highly e cient prion decontamination of surgical
steel surfaces. As part of this project, we used the steel beads RT-QuIC to screen
a total of more than 100 di erent formulations provided by Borer Chemie AG for
their e ciency to inactivate prions on metal surfaces (Fig. 3.8). The most e cient
formulations from every screening round were adapted and improved by Borer
Chemie AG and subjected to further screenings. Formulation 10299.70B at a
concentration of 0.5% was found to be the most e cient formulation for prion
inactivation. It is composed of sodium hypochlorite, tetrapotassium pyrophosphate,
dipotassium trioxosilicate and phosphonate. The e ciency of the formulation was
further tested using di erent treatment times ranging from 5 to 30 min (Fig. 3.9).
A 5 min treatment at 55  C was su cient to completely abolish seeding activity of
RML-coated beads in the RT-QuIC. This decontamination e ciency was comparable
to a 2 h treatment with 1 M NaOH at room temperature, a standard protocol for prion
decontamination. The formulation has great potential as a practically applicable
decontamination product in surgical steel cleaning. The decontamination e ciency
of the lead formulation is further being tested and validated in a cell-based infectivity
assay and in a mouse bioassay by Daniel Heinzer and colleagues.
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Fig. 3.9.: E ciency of lead formulation 10299.70B assessed by RT-QuIC. 100,000 RML-coated steel
beads were treated with formulation 10299.70B for di erent treatment times at 55  C (lower
panel). Untreated beads coated with RML (upper panel, red) and RML-coated beads treated
with NaOH for 2 h at room temperature (upper panel, grey) were used as controls. The
treatment e ciency was assessed using the RT-QuIC assay. ThT fluorescence was recorded
every 15 min over the course of 105 h. All reactions were performed in quadruplicate.
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3.2.4 RT-QuIC with Cerebellar Organotypic Cultured Slices
Antibodies directed against the globular domain of the cellular prion protein (aa
124-230) exert neurotoxic e ects similar to those observed upon prion infection
(Sonati et al., 2013; Reimann et al., 2016). The neurotoxic e ects are mediated by
an e ector domain, the flexible tail at the N-terminus (aa 23-123) of PrPC (Sonati
et al., 2013). Binding of antibodies to the globular domain is thought to cause a
conformational change in the flexible tail region relative to the cell membrane (Sonati
et al., 2013), which activates a pathogenic cascade of intracellular processes leading
to neurodegeneration (Herrmann et al., 2015). Due to the fact that globular domain
binders induce neurodegeneration similar to prion infection, the question arises
whether such antibodies activate prion self-replication processes leading to the
conversion of cellular PrPC to the scrapie isoform PrPSc.
Karl Frontzek and colleagues (Institute of Neuropathology, University Hospital Zurich)
investigated whether the neurotoxic anti-prion antibody POM1 induces formation of
de novo PrPSc (Frontzek et al., 2016). Karl Frontzek treated cerebellar organotypic
cultured slices (COCS) of tga20 mice with POM1 leading to neurodegeneration
in brain slices. He then analysed the POM1-treated COCS homogenates for the
presence of newly formed, proteinase K (PK) resistant PrPSc. In his analyses, he did
not detect any PK-resistant PrPSc in Western blot following PK digestion. In addition,
no PrPSc replication was observed in prion-susceptible CNS-derived CAD5 cells
treated with POM1 COCS homogenates, and PrP-overexpressing tga20 inoculated
with POM1-treated COCS homogenates did not show any signs of a neurological
disease (data published in Frontzek et al., 2016).
To further confirm these findings, we assessed the propagation activity of ho-
mogenates of POM1-treated tga20 COCS using the RT-QuIC assay (Fig. 3.10).
The RT-QuIC reactions were seeded with homogenates of COCS treated with sin-
gle chain variable fragments of POM1 (scFvPOM1) or scFvPOM1 saturated with
recombinant prion protein (recPrP) antigen (scFvPOM1+recPrP). NBH- and RML-
treated COCS homogenates were used as controls. Neither the scFvPOM1- nor the
(scFvPOM1+recPrP)-treated COCS homogenates showed any positive RT-QuIC
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Fig. 3.10.: RT-QuIC analysis of POM1-treated tga20 COCS homogenates. (a) Real-time ThT fluores-
cence time courses of RT-QuIC reactions seeded with 2 µL of NBH- (green), RML- (red),
scFvPOM1- (yellow) or (scFvPOM1+recPrP)-treated (blue) COCS homogenates. NBH-
and RML-treated homogenates were used as positive and negative controls, respectively.
All reactions were performed in quadruplicate. (b) Fluorescence endpoint values of the
RT-QuIC reactions. Horizontal lines indicate group means. Data were statistically analysed
using a one-way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison
testing (*** p < 0.001, n=4). Panel (a) was adapted from Frontzek et al., 2016 under the
terms of the Creative Commons Attribution License.
reaction. In contrast, COCS homogenates treated with RML showed an increase
in the ThT fluorescence after approximately 24 h. These findings indicated the
absence of propagation-active PrPSc in POM1-treated COCS homogenates. Along
with the results from the PK Western blot, the cell-based assay and the mouse bioas-
say, these results show that neurotoxic antibodies targeting the globular domain
of PrP do not induce self-replication of prions, but rather act downstream of prion
self-replication.
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3.3 Discussion and Outlook
Diagnostic RT-QuIC
I successfully established the real-time quaking-induced conversion (RT-QuIC) as-
say for the detection of PrPSc aggregates in tissue samples. Recombinant hamster
PrP was used as substrate for PrPSc-dependent conversion. Small amounts of
pathological aggregates in patient samples induced the conversion of the substrate
protein into detectable aggregates, thereby allowing the diagnosis of CJD from CSF
samples or brain tissue. After the establishment and validation of the method with
CSF samples of known, neuropathologically confirmed diagnostic status, the assay
was implemented in the diagnostic analysis of suspected CJD cases.
Diagnostic assays require a high degree of robustness and reliability. Two multicen-
tre studies have assessed the reproducibility of the diagnostic CSF RT-QuIC across
di erent laboratories (Cramm et al., 2016; McGuire et al., 2016). In international,
blinded ring trial studies they were able to demonstrate almost complete conformity
of the RT-QuIC test results among di erent laboratories, and calculated a sensitivity
of 85–100% and a specificity of 99–100% (Cramm et al., 2016; McGuire et al.,
2016). Ring trial samples tested in our laboratory confirmed these findings. All CJD
samples were correctly identified, and no false positive RT-QuIC reactions were
detected for any of the non-CJD samples. Due to the high diagnostic significance
of the assay, many e orts were undertaken recently to further improve and stan-
dardise the RT-QuIC assay (Cheng et al., 2014; Orrú et al., 2015; Orrú et al., 2016;
Groveman et al., 2017). Faster conversion and enhanced detection of PrPSc was
achieved with an N-terminally truncated PrP substrate, higher assay temperature
or altered solution conditions (Orrú et al., 2015; Cheng et al., 2014). Besides that,
attempts to apply more practical and less invasive procedures of sample collection
resulted in the use of olfactory epithelium samples from nasal brushings (Orrú et al.,
2014). Although not yet standardised, this method holds a great potential for future
diagnostics, as nasal brushings represent a much less invasive intervention than
lumbar puncture or brain biopsies.
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One of the practical limitations of the diagnostic CSF RT-QuIC is its low throughput.
Working with quadruplicates, a 96-well microplate provides space for 21 CSF sam-
ples and 3 control reactions. The long assay duration of 120 h limits the assessment
to one assay plate a week. The assay could be further improved by adapting it to
a 384-well format to allow higher throughput. A di erent microplate format would,
however, require adaptation of the assay conditions to account for altered reaction
volume and surface-volume ratio.
By analogy, the digital amyloid amplification assay described in the previous chapter
could be extended to the RT-QuIC. Rather than relative quantification (Takatsuki
et al., 2015; Henderson et al., 2015), the RT-QuIC could yield exact numbers of
PrPSc propagons. Relating the propagon numbers to clinical symptoms might reveal
interesting aspects of disease progression, and advance our understanding of prion
disease spreading.
Steel Beads RT-QuIC
As a further application of the RT-QuIC assay, I adapted the conventional protocol to
detect prions adsorbed to stainless steel surfaces. The detection of prions bound to
steel beads allowed the assessment of di erent prion decontaminants in inactivating
prions on surgical steel surfaces. Possible side e ects of the beads on the RT-QuIC
conversion reaction were excluded, and the optimal number of beads used to seed
the reaction was determined. At very high bead numbers, false positive RT-QuIC
reactions were detected. This e ect is likely to be caused by the large metal surface
in the assay as was previously reported in a study assessing prions bound to steel
wires using a cell-based scrapie assay (Edgeworth et al., 2010). However, at lower
bead numbers no false positive RT-QuIC reactions were observed.
As a validation of the steel beads RT-QuIC assay, we assessed the propagation-
activity of RML-coated beads treated with two common prion inactivation procedures,
1 M NaOH and 3% SDS. Beads treated with NaOH abolished all propagation activity,
while beads treated with SDS showed a reduced propagation activity when com-
pared with untreated beads. These findings are in agreement with a recent study
assessing prion decontamination of steel wires using the RT-QuIC method, in which
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prions were completely inactivated by NaOH treatment but only partially inactivated
by SDS treatment (Mori et al., 2016). In contrast, earlier findings reporting complete
inhibition of prion transmissibility upon treatment with SDS (Tateishi et al., 1991)
were not confirmed, and corresponding guidelines for decontamination will need to
be revisited.
Prior to the screening of newly generated formulations with potential prion decon-
tamination properties, the e ciency of a set of 7 commercially available decon-
taminants was tested with the steel beads RT-QuIC. Surprisingly, two (ACTANIOS
WD, Neodisher Septoclean) of the three strongly alkaline formulations classified
as prion inactivating by the french ’Agence nationale de sécurité du médicament et
des produits de santé (ANSM, 2015)’, did not show any inactivation in the RT-QuIC
assay. The only e cient decontaminant was ALKA 100. On the basis of these
findings, Borer Chemie AG (Zuchwil) developed new formulations with potential
prion decontamination properties, which were assessed using the steel beads RT-
QuIC. One e cient lead formulation was identified with RT-QuIC, and will be further
validated in a cell-based infectivity assay and in a mouse bioassay.
One of the technical challenges of the steel beads RT-QuIC is the accurate pipetting
of beads. The adhesion of the beads to a variety of surfaces is a source of errors,
which might a ect accuracy of the assay. The loss of beads in every pipetting
step leads to an actual number of beads lower than the calculated number. To
minimise the error, we used the exact same pipetting steps for every sample thereby
reducing the variability between samples. Even though the propagation activity was
reproducible for replicate reactions of most experiments, variability in the lag times
of the replicates was observed in some experiments. A possible way to account for
this technical issue is to perform log reduction experiments in which beads coated
with serial dilutions of RML are treated with di erent formulations. Comparison with
the dilution series of untreated beads would reveal the log reduction in propagation
activity upon decontamination treatment.
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RT-QuIC with Cerebellar Organotypic Cultured Slices
The main scientific application of the RT-QuIC is the investigation of prion propaga-
tion activity. Using the RT-QuIC assay with homogenates of cerebellar organotypic
cultured slices, we were able to confirm the finding that neurotoxic anti-prion antibod-
ies directed against the globular domain of PrPC did not induce PrPSc self-replication.
A methodologically similar organotypic slice culture assay coupled with RT-QuIC
(OSCAR) was published a few month after our report. The publication confirmed
that the combination of organotypic slice culture with RT-QuIC represents an e cient
way of determining prion propagation activity (Kondru et al., 2017)
Generally, the RT-QuIC assay can be used to assess prion self-propagation in
mouse brain homogenate. The e ect of various genes on prion replication can be
investigated by knocking out the respective gene in a transgenic mouse infected
with RML and assessing PrPSc activity in the brain of the knockout animal. New
CRISPR/Cas gene editing tools have drastically facilitated the generation of knock-
out mouse models. In combination with the assessment of PrPSc self-replication by
RT-QuIC this might become a powerful approach to build our understanding of the
basic principles of prion replication.
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3.4 Materials and Methods
3.4.1 Construction of Plasmid Encoding the Gene for HaPrP23 231
A geneblock encoding full-length (23-231) hamster PrP (Genescript) was cloned into
the pRSET A expression vector (Invitrogen) using the NdeI and EcoRI restriction
sites. The sequence of the construct was verified by automated Sanger sequencing
at Microsynth (Balgach, Switzerland).
3.4.2 Expression and Purification of Hamster Prion Protein
HaPrP23 231 was expressed in Rosetta2(DE3)pLysS E.coli cells in Overnight Ex-
press Instant Terrific Broth (TB) Medium (Merck Novagen) containing 100 µg mL 1
carbenicillin and 34 µg mL 1 chloramphenicol for 26 h at 30  C and 90 rpm. Cells
were harvested by centrifugation (10,000 g, 5 min, 4  C), and lysed by two freeze-
thaw cycles. Cytoplasmic inclusion bodies were then washed twice with 1X and
twice with 0.1X BugBuster Protein Extraction Reagent (Novagen) and solubilised in
8 M GdmCl (pH 8.0). After another centrifugation step at 17,000 g for 10 min, the
supernatant was subjected to an a nity chromatography using Ni2+-nitrilotriacetic
acid Superflow resin (QIAGEN). The protein was refolded and purified on column by
running a linear gradient from 100 mM NaH2PO4, 10 mM Tris-HCl, 6 M GdmCl (pH
8.0) to 100 mM NaH2PO4, 10 mM Tris-HCl (pH 8.0) over 3.5 h. After elution with a
linear gradient to pre-cooled 500 mM imidazol, 100 mM NaH2PO4, 10 mM Tris-HCl
(pH 6.0), the protein containing fractions were combined and filtered through a 0.2
µm syringe filter. The purified protein was dialysed against 200 mM NaH2PO4 (pH
5.8) and concentrated to a final protein concentration of 0.6-0.8 mg mL 1 prior to
storage at -80  C.
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3.4.3 Real-Time Quaking-Induced Conversion Assay
RT-QuIC assays were performed using recombinant full-length hamster prion protein
(HaPrP23 231) as substrate for PrPSc-catalysed conversion as previously described
(Wilham et al., 2010). Recombinant HaPrP was filtered using 100 kDa centrifugal
filters (Pall Nanosep OD100C34), and adjusted to a final concentration of 0.1 mg
mL 1 in PBS (pH 7.4, including 130 mM NaCl) containing 170 mM NaCl, 10 µM
EDTA, 10 µM thioflavin T in a total reaction volume of 100 µL per well (including
seed volume). RT-QuIC reactions were seeded with 2 µL of brain homogenate or 30
µL of CSF. All RT-QuIC reactions were performed in quadruplicate in black 96-well
polystyrene microplates (Nunc, Prod. No. 265301) covered with sealing tape (Nunc,
Prod. No. 232702). The reactions were amplified over a time period of 105 hours
at 42  C with alternating cycles of 90 s shaking at 900 rpm in double orbital mode
and 30 s resting using a FLUOstar Omega microplate reader (BMG Labtech). The
amplification of de novo aggregates was followed in real-time by measuring the
increase in thioflavin T fluorescence (ex/em 450/480 nm) every 15 min in bottom
read mode.
3.4.4 Ring Trial Materials
Recombinant HaPrP23 231 and 10 CSF samples for the ring trial were kindly provided
by the National CJD Research & Surveillance Unit, Edinburgh, United Kingdom.
Of the 10 CSF samples, 1 was from a patient with confirmed sCJD, 4 were from
patients with probable sCJD (diagnosed according to the World Health Organisation
criteria), and 5 samples were from non-CJD patients. The samples included 6 males
and 4 females within the age range of 44 to 82. The samples were shipped on dry
ice, and stored at -80  C until usage. The CSF RT-QuIC with the ring trial samples
was performed as described in the section ’Diagnostic CSF RT-QuIC’.
70 Chapter 3 Real-Time Quaking-Induced Conversion Assay
3.4.5 Diagnostic RT-QuIC
Sample handling and processing of brain tissue and cerebrospinal fluid samples are
described below. Experimental details of the assay are given in section ’Real-Time
Quaking-Induced Conversion Assay’. The results of the diagnostic RT-QuIC were
scored positive if 3 or 4 RT-QuIC responses out of 4 replicate reactions were positive;
with 0 or 1 positive RT-QuIC response out of 4 replicate reactions, the RT-QuIC
result was scored negative.
Brain Tissue Samples
Human brain tissue was obtained from our brain biobank or from autopsies of
suspected CJD cases. Aliquots of 10% (w/v) brain homogenate in 0.32 M sucrose
were thawed on ice immediately before the RT-QuIC assay. The brain homogenates
were diluted 20,000-fold using PBS containing N2 supplement (Thermo Fisher). 2
µL of the diluted brain homogenates were added to the RT-QuIC reaction mixture
adding up to a total reaction volume of 100 µL per well.
Cerebrospinal Fluid Samples
Cerebrospinal fluid was obtained from suspected CJD cases. CSF samples were
stored at -80  C and thawed on ice immediately before the RT-QuIC assay. 30, 15
and 7.5 µL of undiluted CSF were added to the RT-QuIC reaction mixture adding up
to a total reaction volume of 100 µL per well.
3.4.6 Steel Beads RT-QuIC
All coatings and decontamination treatments of steel beads were performed by
Daniel Heinzer. Details can be found in his Master thesis entitled ’Establishing
methods to detect surface-bound scrapie prion protein on surgical steel’ (Heinzer,
2016).
Steel beads were dissolved in PBS, diluted to the final bead number and stored at
-20  C until usage. To minimise the error in bead number arising from inaccurate
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pipetting (some beads adhered to the pipette tips or to the tube walls), all samples
were treated identically and diluted using the same dilution steps. In addition,
samples were thoroughly mixed to suspend the beads by vigorous vortexing before
every pipetting. RT-QuIC was performed as described in the section ’Real-Time
Quaking-Induced Conversion Assay’. RT-QuIC reactions were seeded with 30 µL of
the bead samples in a total reaction volume of 100 µL.
3.4.7 COCS RT-QuIC
Preparation and treatment of cerebellar organotypic cultured slices were performed
by Karl Frontzek as described previously (Frontzek et al., 2016).
RT-QuIC reactions were seeded with 2 µL of scFvPOM1- or (scFvPOM1+recPrP)-
treated tga20 COCS homogenates (0.5 ng µL 1 total protein concentration in
N2/PBS, diluted 6000-fold from an initial total protein concentration of 3000 µg
mL 1 of COCS homogenate) in a total reaction volume of 100 µL. NBH- and RML-
treated tga20 COCS homogenates were used as negative and positive controls,
respectively.
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4↵-Synuclein Amyloid Amplification
Assay
4.1 Introduction
The accumulation and inclusion of misfolded ↵-synuclein is the main hallmark of
Parkinson’s disease and other ↵-synucleinopathies. Despite their high abundance
in diseased brains, the detection of pathologic aggregates in easily accessible tis-
sues remains elusive. In this chapter, I describe my work to develop an assay for
the sensitive detection and quantification of ↵-synuclein aggregates. The assay is
capable of detecting low abundance amyloid aggregates and therefore allows the
biochemical diagnosis of ↵-synuclein aggregation. Furthermore, I applied the assay
to investigate the inactivation of ↵-synuclein aggregates on steel surfaces using
di erent decontamination reagents.
Parts of this chapter are reproduced or quoted verbatim from the following manuscript in preparation:
↵-Synuclein Amyloid AmplificationAssay for theAbsoluteQuantification of↵-Synuclein Propagons
Manuela Pfammatter, Daniel Heinzer, Rita Moos, Lisa Caflisch, Adriano Aguzzi, and Simone Horne-
mann
manuscript in preparation
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4.2 Results
4.2.1 Expression and Purification of Human ↵-Synuclein
The production of large amounts of highly pure human ↵-synuclein represents an
essential prerequisite for the development of an ↵-synuclein amyloid amplification
assay. To improve purity and expression yield of the protein, a codon-optimised
version of the SNCA gene encoding human ↵-synuclein was cloned into a pRK172
expression vector, and the purification protocol was optimised based on two pre-
viously described protocols (Hoyer et al., 2002; Volpicelli-Daley et al., 2014). To
avoid dimerisation due to an erroneously incorporated cysteine residue at position
136, the respective codon was mutated from the triplet TAC to TAT (Cys to Tyr) as
suggested previously (Masuda et al., 2006). The mutated expression vector was
transformed into E. coli BL21(DE3)RIL, and cells were grown overnight to induce
protein expression. The overexpressed protein was purified from the cytoplasm
using a sequence of heat denaturation of unwanted proteins, DNA precipitation,
ammonium sulphate ((NH4)2SO4) precipitation, anion exchange chromatography
(IEC) and size exclusion chromatography (SEC). The purity of the sample was
analysed by SDS-PAGE after each purification step (Fig. 4.1a). The identity of the
purified protein was confirmed by ESI-MS (Fig. 4.1b). A single peak at m/z 14,460
indicated the presence of pure human ↵-synuclein (expected MW: 14,460 Da). The
optimised purification protocol resulted in an average yield of 100 mg of pure protein
per litre of bacterial culture, which was used as monomeric substrate in the assay
and for the reconstitution of preformed fibrillar seeds.
4.2.2 ↵-Synuclein Standard Fibril Sample
A stable sample of↵-synuclein fibrils with reproducible seeding properties is crucial to
establish conditions for the specific, template-catalysed amplification of ↵-synuclein
amyloid fibrils. Therefore, an ↵-synuclein standard fibril sample was generated from
recombinant, monomeric ↵-synuclein. Highly pure, monomeric ↵-synuclein was
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Fig. 4.1.: Purification of recombinantly produced human ↵-synuclein. (a) SDS-PAGE analysis of
samples after every purification step. Highly pure protein obtained after the final purification
step is loaded in the rightmost lane. The highly overexpressed protein band indicated by a
black arrowhead corresponds to ↵-synuclein. The gel was stained with Coomassie protein
stain (InstantBlue, Expedeon). (b) Electrospray ionisation mass spectrometry of purified
↵-synuclein (expected molecular weight 14,460 Da).
diluted to 5 mg mL 1 using PBS, and incubated at 37  C, 1000 rpm for 7 days. At
the end of the incubation, the sample was visibly turbid, indicative of the formation
of fibrils in the sample. To confirm the formation of fibrils and to estimate the fraction
of fibrils relative to residual monomeric protein, the sample was analysed using a
fibril sedimentation assay as previously described (Volpicelli-Daley et al., 2014).
The incubated sample was ultracentrifuged to separate fibrils from soluble protein,
and the protein content in the pellet fraction and soluble fraction was estimated by
SDS-PAGE analysis (Fig. 4.2). ↵-Synuclein was detected in both the soluble and
the insoluble fraction. The majority of the protein was present in the pellet fraction
in the form of insoluble fibrillar aggregates. The ratio of fibrillar versus monomeric
protein was constant between di erent preparations of ↵-synuclein fibril samples.
To avoid fibril dissociation, which reduces the propagation activity of the sample,
fibril samples were stored in small aliquots at -20  C.
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Fig. 4.2.: SDS-PAGE analysis of the fibril sedimentation assay for the confirmation of ↵-synuclein
fibrillar aggregates. After ultracentrifugation, residual monomeric protein appeared in the
soluble supernatant fraction, insoluble ↵-synuclein fibrils in the pellet. The gel was stained
with Coomassie protein stain (InstantBlue, Expedeon).
4.2.3 ↵-Synuclein Amyloid Amplification Assay
To reliably detect minute amounts of ↵-synuclein aggregates through amplification,
it is crucial to perform the amplification reaction under conditions, which selectively
enhance template-catalysed conversion of the monomer into fibrils while suppress-
ing spontaneous fibrillation through primary nucleation. Therefore, I studied the
e ect of di erent amplification conditions (bu er, pH, salts, monomer concentration,
temperature, shaking cycles) on the fibrillation of monomeric ↵-synuclein into fibrillar
aggregates in the presence and absence of preformed ↵-synuclein fibrils (PFFs). I
started with solution conditions that had previously been shown to e ciently promote
secondary nucleation events, that is conditions favouring propagon-catalysed fibrilla-
tion of ↵-synuclein (Buell et al., 2014). This allowed me to establish assay conditions
for the amplification of ↵-synuclein aggregates specifically through self-replication.
At mildly acidic pH (sodium acetate bu er, NaOAc, pH 5.2), the seeded conversion
was highly e cient, while spontaneous nucleation was suppressed over the course
of the experiment (24 h). In the reactions seeded with preformed fibrils, aggregation
onset was observed after a lag time of less than 4 hours. To determine the detection
limit of the assay, I performed serial limiting dilutions of preformed fibrils to generate
a standard curve of propagation activity (Fig. 4.3a). Aggregates were detectable in
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Fig. 4.3.: Standard curve of aggregation of human ↵-synuclein. (a) Real-time ThT fluorescence time
courses of ↵-synuclein aggregation. Reactions of 10 µM of monomeric ↵-synuclein in 10
µM Thioflavin T (ThT), 25 mM NaOAc (pH 5.2) were seeded with 10-fold serial dilutions
from 103 to 1012 of preformed fibrils (coloured). Only bu er was added to unseeded control
reactions (black). ThT fluorescence was recorded every 5 min over the course of 24 h.
All seeded and control reactions were performed in quadruplicate. (b) Standard curve of
↵-synuclein aggregation relating the fraction of positive wells to the logarithm of the dilution
factor. A Poisson distribution was fitted to the data (grey line) to quantify the number of
propagons in the original fibril sample.
reactions seeded with as low as femtomolar concentrations (in monomer equiva-
lents) of preformed fibrils, which likely corresponds to single propagons assuming
an average fibril is build from several hundred monomers. At higher dilutions (>1010-
fold dilution), no propagation activity was detected. The fraction of positive wells was
related to the logarithm of the dilution factor (Fig. 4.3b), and a Poisson distribution
was fitted to the data to quantify the number of ↵-synuclein propagons in the original
fibril sample. The best fit yielded an average of 1.6 · 1013 propagons per µL.
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4.2.4 Steel Beads ↵-Synuclein Amyloid Amplification Assay
Recent reports of prion-like spreading of ↵-synuclein have raised the question of
whether pathological ↵-synuclein aggregates can be transmitted between individuals
(Beekes et al., 2014). This poses the potential risk of iatrogenic transmission through
insu ciently decontaminated instruments in medical or surgical procedures. In a
collaborative project with Daniel Heinzer (Institute of Neuropathology, University
Hospital Zurich), we investigated the potential to deactivate ↵-synuclein aggregates
on steel surfaces using a set of conventional prion decontaminants. Daniel Heinzer
coated 316L stainless steel beads with preformed ↵-synuclein fibrils and applied
di erent decontamination reagents to inactivate the fibrils. Subsequently, I used the
↵-synuclein amyloid amplification assay to assess the decontamination e ciency of
the di erent decontaminants.
Development of the Steel Beads ↵-Synuclein Amyloid Amplification Assay
Analogous to the steel beads RT-QuIC (see 3.2.3 Steel Beads RT-QuIC), I modi-
fied the ↵-synuclein amyloid amplification assay to detect ↵-synuclein aggregates
adsorbed to steel beads. To study possible side e ects of the steel beads on
the aggregation assay, particularly false positive or false negative aggregation, I
investigated conversion reactions seeded with non-coated beads as well as with
beads coated with monomeric and fibrillar ↵-synuclein. Steel beads were treated
for coating with PBS, monomeric and fibrillar ↵-synuclein and washed thoroughly
to remove unbound material by Daniel Heinzer. The coated beads and the non-
coated control beads were added as seeds to the amplification reaction (Fig. 4.4).
Steel beads treated with preformed ↵-synuclein fibrils seeded the conversion of
monomeric ↵-synuclein into aggregated ↵-synuclein e ciently. Amplification re-
actions seeded with as low as 15 steel beads (calculated bead number) showed
monomer-to-aggregate conversion. At high bead numbers (15,000 to 150 beads), all
four replicate reactions showed an increase in the ThT fluorescence signal, whereas
only half of the replicate reactions were fluorescence positive after 24 h for the
reactions seeded with 15 beads. Lower bead numbers and uncoated control beads
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Fig. 4.4.: Steel beads ↵-synuclein amyloid amplification assay with 316L steel beads coated with
monomeric and fibrillar ↵-synuclein. Between 15,000 and 1.5 non-coated control beads
(grey), beads coated with monomeric ↵-synuclein (green) and beads coated with preformed
↵-synuclein fibrils (red) were used to seed amplification reactions. ThT fluorescence was
recorded every 15 min over the course of 24 h (respectively 22 h for reactions seeded with
beads treated with monomeric ↵-synuclein, which stopped early due to a technical issue).
All reactions were performed in quadruplicate.
did not cause aggregation in any of the amplification reactions. Similarly, beads
coated with monomeric ↵-synuclein did not lead to aggregation except for one false
positive aggregation signal at the lowest bead number. The long lag time before
aggregation onset and the fact that aggregation was observed at the lowest bead
number indicate that the aggregation was caused by spontaneous nucleation rather
than by the steel beads.
Taken together, the use of steel beads did not a ect the conversion in the ↵-synuclein
amyloid amplification assay. The results did not only show the high binding a nity
of ↵-synuclein fibrils to stainless steel beads, but in addition they proved the utility
of the amplification assay as a readout for assessing the contamination of steel
surfaces with ↵-synuclein.
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Fig. 4.5.: Decontamination of steel beads coated with ↵-synuclein fibrils. 316L steel beads coated
with ↵-synuclein fibrils were treated with di erent decontaminants (1 M NaOH, 2% NaOCl,
1% SDS, 70% HCOOH, 1% Hellmanex, 1% LpHse) for 1 h at room temperature. 15,000 to
1.5 beads were added to the ↵-synuclein amplification reactions, and the time course of the
ThT fluorescence was monitored over 24 h. All reactions were performed in eight technical
replicates.
Decontamination of Steel Beads Coated with ↵-Synuclein Fibrils
The steel beads ↵-synuclein amyloid amplification assay was used to study the
e ciency of six conventional decontaminants:
1 M NaOH, 2% NaOCl, 1% SDS, 70% HCOOH, 1% Hellmanex (Hellma Analytics),
1% LpHse (Steris).
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316L steel beads coated with ↵-synuclein were treated with the decontaminants
for 1 h at room temperature, and after treatment, their propagation activity was
assessed using the amplification assay (Fig. 4.5). Beads incubated in ddH2O were
used as control samples with a high propagation activity. The highly e cient prion
decontaminant NaOH (1 M) was not e cient in decontaminating ↵-synuclein fibrils.
At the highest bead number, all replicate reactions were ThT fluorescence positive,
and at 150 beads, 25% of the replicate reactions showed ThT positivity at the assay
endpoint. Similar propagation activities were observed for beads decontaminated
with 1% SDS and 1% Hellmanex. The phenolic, acidic prion decontaminant LpHse
showed a slightly better decontamination e ciency. At the highest bead number
tested, three out of eight replicate reactions showed a positive ThT signal. Even
though the propagation activity of samples treated with LpHse was lower than
the activity of the control samples, the overall decontamination activity of LpHse
was insu cient. The most e cient inactivation was achieved with 2% NaOCl and
70% HCOOH. Both NaOCl and HCOOH treatment resulted in almost complete
inactivation of ↵-synuclein propagons.
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Fig. 4.6.: ↵-Synuclein amyloid inactivation e ciency of di erent decontaminants. Propagation activity
curves showing the fraction of positive replicates for serial tenfold dilutions of 316L steel
beads treated with di erent decontaminants (1 M NaOH, 2% NaOCl, 1% SDS, 70% HCOOH,
1% Hellmanex, 1% LpHse). Data represent the mean ± SD from three independent
experiments. A Poisson distribution was fitted to the data (solid lines) to estimate the
propagation activity of the inactivated beads.
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4.2.5 Towards a Diagnostic ↵-Synucleinopathy Blood Assay
The sensitive detection of ↵-synuclein aggregates in body tissues or fluids enables
the biochemical diagnosis of ↵-synucleinopathies in a minimally-invasive way. After
having established conditions for the specific amplification of ↵-synuclein aggregates,
we decided to develop a blood-based assay to detect ↵-synuclein aggregates in
patient samples. The reliable detection of aggregates in such an easily accessible
body fluid would take diagnosis of ↵-synucleinopathies to a new level.
E ect of Blood on the Template-Catalysed Conversion of ↵-Synuclein
The selective amplification of amyloid propagons in complex mixtures such as blood
constitutes a big challenge. Blood proteins and other factors dissolved in blood
might interfere with the conversion reaction. To determine the e ect of blood on the
conversion of ↵-synuclein, I first performed preliminary experiments of unseeded and
seeded conversion reactions of ↵-synuclein spiked with blood drawn from healthy
C57BL/6J mice (Fig. 4.7).
In a first step, unseeded reactions were spiked with blood plasma, serum and red
blood cells to investigate if blood components cause spontaneous, false positive
aggregation of monomeric ↵-synuclein (Fig. 4.8). Unseeded conversion reactions
spiked with blood plasma or serum showed a negligibly low level of spontaneously
converting, false positive reactions. In contrast, reactions spiked with red blood
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Fig. 4.7.: Schematic of preliminary experiments to investigate the e ect of blood on unseeded and
seeded conversion of ↵-synuclein. Blood from healthy C57BL/6J mice was collected into
blood collection tubes and processed into plasma, serum and red blood cells. Blood plasma,
serum and red blood cells were added to unseeded and seeded ↵-synuclein conversion
reactions to study e ects on the conversion.
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cells showed a slightly elevated number of false positive reactions. In addition, I
found that spontaneous aggregation was triggered by cryoprecipitates that form
upon thawing at 4  C or by fresh, non-hemolysed blood samples. Spontaneous
aggregation was prevented by repeated freeze-thaw cycles using a waterbath at 37
 C for thawing.
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Fig. 4.8.: E ect of blood on unseeded conversion of ↵-synuclein. Real-time ThT fluorescence time
courses of unseeded ↵-synuclein amyloid amplification reactions spiked with mouse blood.
Blood plasma, serum and red blood cells were serially diluted tenfold in assay bu er and
added to unseeded ↵-synuclein amplification reactions containing 10 µM monomeric ↵-
synuclein, 10 µM ThT in 25 mM NaOAc (pH 5.2). Control reactions were spiked with 25 mM
NaOAc (pH 5.2). All reactions were performed in quadruplicate.
In a second step, reactions seeded with preformed ↵-synuclein fibrils were spiked
with blood plasma, serum and red blood cells to investigate if blood components
might further a ect the seeded conversion (Fig. 4.9). All blood samples were found
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Fig. 4.9.: E ect of blood components on the seeded conversion of ↵-synuclein. (a) Real-time ThT
fluorescence time courses of seeded ↵-synuclein amyloid amplification reactions spiked
with various mouse blood components. Blood plasma, serum and red blood cells were
serially diluted tenfold in assay bu er and added to ↵-synuclein amplification reactions
containing 10 µM monomeric ↵-synuclein, 10 µM ThT, 10 nM preformed ↵-synuclein fibrils
in 25 mM NaOAc (pH 5.2). Control reactions were spiked with 25 mM NaOAc (pH 5.2).
All reactions were performed in quadruplicate. (b) SDS-PAGE analysis of soluble (s) and
insoluble fractions (p) of conversion reactions spiked with blood plasma and bu er control.
The endpoint sample of reactions spiked with undiluted (1x) and 103-fold diluted plasma
were analysed after ultracentrifugation.
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to have an inhibitory e ect on the seeded conversion. The addition of 2.5 µL of pure
plasma, serum or red blood cells in a total reaction volume of 50 µL was su cient
to completely prevent the template-catalysed amplification of amyloid fibrils. Over
the course of 24 h no increase in ThT fluorescence was observed (Fig. 4.9a), and
ultracentrifugation of the samples at the endpoint showed that all protein remained in
the soluble fraction (Fig. 4.9b). Dilution of the blood samples prevented the inhibitory
e ect. At a 103-fold dilution of the blood samples the observed propagation activity
was comparable to the propagation activity of a control sample not containing any
blood components.
Even though diluting blood samples is a possible solution to prevent inhibitory
e ects of the blood matrix, it lowers the aggregate concentration in the analyte and
complicates the sensitive detection of ↵-synuclein aggregates. Therefore, I suggest
an appropriate pretreatment of blood samples to reduce blood matrix e ects without
lowering the aggregate concentration.
Blood Pretreatment Strategies to Enrich ↵-Synuclein Aggregates
Sample pretreatment can either involve an enrichment step in which the blood
matrix is removed and ↵-synuclein aggregates are enriched or a capturing step in
which aggregates are specifically extracted from the blood. In both approaches the
blood matrix is removed, while the amyloid aggregates are accumulated. In prion
research, many pretreatment strategies have been used to enrich prion aggregates
from body fluids (Orrú et al., 2011; Elder et al., 2015; Concha-Marambio et al.,
2016; Bougard et al., 2016). I adapted five pretreatment strategies to enrich ↵-
synuclein aggregates from patient blood samples prior to amplification in the ↵-
synuclein amyloid amplification assay: ultracentrifugation, sarkosyl precipitation,
sodium phosphotungstic acid (NaPTA) precipitation, steel beads capturing, and
immunoprecipitation.
Sarkosyl solubilisation. A common strategy to purify prion aggregates from blood is
the removal of the blood matrix by sarkosyl solubilisation (Concha-Marambio et al.,
2016). Sarkosyl (N-laurylsarcosine) is a harsh detergent used to solubilise blood
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Fig. 4.10.: Sample pretreatment strategies. Amyloid aggregates can either be isolated from blood
samples by concentrating the aggregates and removing the blood matrix (upper strategy)
or by specifically capturing the aggregates from the blood (lower strategy).
proteins and other blood components. In contrast, pathologic prion aggregates are
sarkosyl insoluble and and can therefore be separated from the sarkosyl-soluble
blood fraction.
I tested the stability of synthetic ↵-synuclein aggregates when solubilising the blood
matrix with sarkosyl. I spiked preformed ↵-synuclein fibrils into the blood of healthy
humans and analysed their propagation activity (Fig. 4.11). I found that sarkosyl-
treated EDTA whole blood spiked with preformed ↵-synuclein aggregates was
propagation active, while sarkosyl-treated blood without fibrils did not show any
propagation activity. Accordingly, synthetic ↵-synuclein fibrils treated with sarkosyl
were insoluble and showed normal propagation activity. Furthermore, sarkosyl did
not cause any false positive, spontaneous aggregation of monomeric ↵-synuclein.
In a next step, I used blood from both healthy donors and patients su ering from PD
to investigate if sarkosyl-solubilisation is adequate for sample pretreatment. EDTA
whole blood was solubilised with 15% sarkosyl, and ultracentrifuged to separate
insoluble aggregates from solubilised components. Pellets were dissolved in 25 mM
NaOAc (pH 5.2) and added to the amyloid amplification assay to analyse the prop-
agation activity (Fig. 4.12). Most blood samples from PD patients showed one or
more propagation-positive reaction out of four replicate reactions. The observed lag
times varied greatly between di erent patient samples but also within the replicates
of a single patient sample. Despite the variability, most samples showed low-level
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Fig. 4.11.: Sarkosyl solubilisation of human blood spiked with preformed ↵-synuclein fibrils. Real-time
ThT fluorescence time courses of ↵-synuclein amyloid amplification reactions seeded with
preformed ↵-synuclein fibrils dissolved in sarkosyl-solubilised whole blood. Fibrils were
dissolved in healthy human EDTA whole blood, and the mixture was solubilised with 15%
sarkosyl before addition to the reaction mastermix (green, final fibril concentration of 10
nM). Fibrils solubilised in sarkosyl (blue), blood solubilised with sarkosyl (red) and pure
sarkosyl (light pink) were used as controls as well as seeded and unseeded plate control
reactions. All reactions were performed in quadruplicate.
propagation activity. In contrast, blood samples from healthy donors were mostly
ThT negative, a few false positive reactions were observed. The spontaneously
aggregating reactions seeded with healthy patient samples were indicative of incom-
plete solubilisation of the blood matrix. In light of the false positive reactions from
healthy donor samples, the propagation activity observed for the PD samples can
not be considered as significant. In order to reliably discriminate between aggregate
positive and negative samples, a more rigorous sample pretreatment with more
e cient solubilisation and enrichment of aggregates is required.
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Fig. 4.12.: Sarkosyl solubilisation of human blood samples from healthy donors and PD patients.
Real-time ThT fluorescence time courses of ↵-synuclein amyloid amplification reactions
seeded with sarkosyl-solubilised whole blood from healthy donors (grey) and PD patients
(red). Four representative examples of reaction time courses of both healthy donors and
PD patients are shown. All reactions were performed in quadruplicate.
NaPTA precipitation. Sodium phosphotungstic acid (NaPTA) precipitation is a
method described to specifically enrich insoluble prion aggregates from blood (Elder
et al., 2015). Phosphotungstate anions bind prion aggregates and separate them
from other factors by facilitating their precipitation (Levine et al., 2015). NaPTA
precipitation has also been successfully applied to purify ↵-synuclein aggregates
from brain tissue (Woerman et al., 2015). These findings suggest that NaPTA precip-
itation could be applied to accumulate ↵-synuclein aggregates from patient blood.
To improve solubilisation, I used harsh sarkosyl conditions (2% sarkosyl for 2 h
at 37  C), which reduced the number of spontaneously aggregating reactions. I
applied the improved sarkosyl solubilisation protocol followed by NaPTA precipitation
pretreatment to blood samples from PD and healthy control patients (Fig. 4.13).
The improved sarkosyl solubilisation was e cient in solubilising all blood compo-
nents from healthy donor samples, resulting in no false positive reactions. However,
we detected only a small fraction of propagation-positive reactions in the reactions
seeded with PD-positive patient samples. The lag times of the aggregating reactions
were comparable among di erent patient samples with an early aggregation onset
(shorter than 5 hours). The short lag times were similar to the lag times of reactions
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Fig. 4.13.: NaPTA precipitation of human blood samples from healthy donors and PD patients. Real-
time ThT fluorescence time courses of ↵-synuclein amyloid amplification reactions seeded
with NaPTA precipitated whole blood from healthy donors (grey) and PD patients (red).
Four representative examples of reaction time courses of both healthy donors and PD
patients are shown. Instead of the usual 24 h, the assay stopped after 23 h due to a
technical issue. All reactions were performed in quadruplicate.
seeded with synthetic ↵-synuclein aggregates, which indicates that the observed
aggregation was induced through seeds rather than due to spontaneous aggregation
events.
Steel beads capturing. Another strategy to enrich amyloid aggregates from blood is
specific capturing of the aggregates. Prions and other amyloids have been shown to
adsorb to metal surfaces (Zobeley et al., 1999). I found that ↵-synuclein aggregates
also strongly bind to steel beads, and that the beads transmit the propagation
activity of the adsorbed ↵-synuclein aggregates (see section 4.2.4 Steel Beads
↵-Synuclein Amyloid Amplification Assay). I therefore investigated whether steel
beads capturing pathological ↵-synuclein aggregates from patient blood can be
used as a pretreatment of blood samples to enrich aggregates for the ↵-synuclein
amyloid amplification assay.
EDTA whole blood samples from healthy donors and PD patients were incubated
overnight with 316L stainless steel beads to capture aggregates. The beads were
then used to seed the amplification assay (Fig. 4.14). Similar as for the NaPTA
precipitation pretreatment, little propagation activity was observed in the reactions
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seeded with beads treated with blood from PD patients. No propagation activity was
detected in reactions seeded with beads treated with blood from healthy donors. Due
to weak signals in the samples from PD patients, no clear discrimination between
samples from PD patients and healthy donors was possible.
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Fig. 4.14.: Steel beads capture of ↵-synuclein aggregates from human blood samples. Real-time ThT
fluorescence time courses of ↵-synuclein amyloid amplification reactions seeded with steel
beads incubated with whole blood from healthy donors (grey) and PD patients (red). Two
representative examples of reaction time courses of both healthy donors and PD patients
at di erent bead numbers are shown. All reactions were performed in quadruplicate.
Immunoprecipitation. In a fourth approach, I used immunoprecipitation to enrich
↵-synuclein aggregates from patient blood. The combination of amyloid capturing
by immunoprecipitation followed by an amplification step has previously been de-
scribed to detect prions in blood components (Orrú et al., 2011; Bougard et al.,
2016). Analogous to these studies, I used magnetic beads coupled to the anti-↵-
synuclein antibody syn211 (binding to the epitope of aa 120–140 at the C-terminus)
to capture ↵-synuclein from blood samples. After capturing, beads were added to
the amplification reactions in the ↵-synuclein amyloid amplification assay to detect
their propagation activity.
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As a proof-of-concept experiment, I captured bothmonomeric and fibrillar↵-synuclein
that were spiked into the blood of healthy donors, and analysed the propagation
activity of the beads (Fig. 4.15). To prevent spontaneous aggregation caused by
bead-induced shear forces, the shaking cycle was lowered to a short 60 s shaking at
low intensity (100 rpm) before each read. Under these conditions, no spontaneous
aggregation was observed in the reactions seeded with uncoupled magnetic beads.
Similarly, beads treated with monomeric ↵-synuclein did not show any propagation
activity. However, beads treated with synthetic ↵-synuclein fibrils both pure and
spiked in healthy blood showed high propagation activity in the amplification assay.
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Fig. 4.15.: Immunoprecipitation of human blood spiked with monomeric and fibrillar ↵-synuclein. Real-
time ThT fluorescence time courses of ↵-synuclein amyloid amplification reactions seeded
with magnetic Dynabeads that were treated with monomeric and fibrillar ↵-synuclein from
whole blood. Monomeric protein (green) and fibrils (dark blue) were dissolved in healthy
human EDTA whole blood, and the mixture was incubated with magnetic Dynabeads coated
with the anti-↵-synuclein antibody syn211 for capturing ↵-synuclein. Subsequently, beads
were added to the reaction mastermix and subjected to amplification. Beads capturing
pure fibrils (red) and empty beads without anti-↵-synuclein antibody (light blue) were used
as controls as well as seeded (purple) and unseeded (grey) plate control reactions. All
reactions were performed in quadruplicate.
Next, I used immunoprecipitation to capture ↵-synuclein from human blood samples
of PD patients and healthy donors. Magnetic beads coupled to syn211 antibody
were mixed with blood samples, and added to the amplification assay to assess
their propagation activity (Fig. 4.15). While blood samples from healthy donors
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did not show any reactivity, most samples from PD patients showed propagation
activity in the amplification assay. In the majority of the tested PD-positive blood
samples, one or more reactions showed an increase in ThT fluorescence after a lag
time of approximately 10–15 hours. These results indicate that there is a low level
of propagation-active ↵-synuclein aggregates specifically in the blood of diseased
patients. Yet a clear discrimination between PD-positive and PD-negative samples
was not possible. This, however, might reflect a heterogeneity in the aggregate load
in PD patients.
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Fig. 4.16.: Immunoprecipitation of ↵-synuclein from human blood samples of healthy donors and PD
patients. Real-time ThT fluorescence time courses of amplification reactions seeded with
↵-synuclein amyloid amplification reactions seeded with magnetic Dynabeads capturing
↵-synuclein from whole blood of healthy donors (grey) and PD patients (red). Four
representative examples of reaction time courses of samples from both healthy donors
and PD patients are shown. All reactions were performed in quadruplicate.
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4.3 Discussion and Outlook
↵-Synuclein Amyloid Amplification Assay
In this chapter, I describe the development of an amyloid amplification assay for
↵-synuclein, the protein involved in Parkinson’s disease and other synucleinopathies.
Recombinant human ↵-synuclein expressed from a codon optimised plasmid was
used as a substrate for propagon-catalysed conversion. In vitro reconstituted ↵-
synuclein fibrils very e ciently seeded the conversion of monomeric protein after a
lag time of less than 4 h, which allowed the detection of single propagating units.
Analogous to the digital insulin amyloid amplification assay, digital serial dilution of
the analyte sample allowed the quantification of the absolute number of ↵-synuclein
propagons in the analyte. A quantitative assay for ↵-synuclein propagons based on
their propagation activity has not been described to date.
Compared to recently published ↵-synuclein conversion assays (Fairfoul et al., 2016;
Shahnawaz et al., 2017; Sano et al., 2017), our assay is more robust and practical.
The observed lag times are highly reproducible and much shorter than the lag times
of more than 70 h reported for other ↵-synuclein conversion assays (Fairfoul et al.,
2016; Shahnawaz et al., 2017; Sano et al., 2017). The comparably short lag times
resulted in a dramatic decrease in total assay duration. Reactions seeded with
synthetic ↵-synuclein fibrils reached a plateau after approximately 4 h compared
to more than 70 h in previously published assays (Shahnawaz et al., 2017). The
shorter measurement time allows for a significant increase in the throughput of the
assay.
Steel Beads ↵-Synuclein Amyloid Amplification Assay
Recent studies have provided evidence for prion-like transmission of ↵-synuclein
pathology (Mougenot et al., 2012; Luk et al., 2012a; Masuda-Suzukake et al., 2013).
Together with ↵-synuclein aggregates being remarkably stable and resistant to
denaturation (Woerman et al., 2017), these findings have raised the concern of a
potential risk of iatrogenic transmission of ↵-synucleinopathies through contact with
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contaminated medical instruments (Beekes et al., 2014). Therefore, the identification
of e cient ↵-synuclein decontamination procedures might be important for the inac-
tivation of potentially hazardous ↵-synuclein fibrils. I applied the ↵-synuclein amyloid
amplification assay to study the e ciency of potential decontamination reagents
for ↵-synuclein amyloid inactivation. Similar to the steel beads RT-QuIC, I adapted
the ↵-synuclein amyloid amplification assay to detect ↵-synuclein propagons ad-
sorbed to steel beads. Preliminary validation experiments showed that the steel
beads ↵-synuclein amyloid amplification assay was capable of detecting synthetic
↵-synuclein fibrils bound to 316L steel beads with a very high a nity. Unspecific
reactions due to the beads were not observed, which allowed me to use this modified
assay for decontamination studies.
Previous studies reported the successful application of prion-e ective decontam-
inants in ↵-synuclein inactivation (Thomzig et al., 2014). NaOH and SDS were
shown to e ciently reduce ↵-synuclein aggregates (Thomzig et al., 2014), and
other decontaminants such as NaOCl, LpHse or Hellmanex were proposed for ↵-
synuclein decontamination (Bousset et al., 2016). We therefore set out to examine
the decontamination potential of the most commonly used prion decontaminants:
NaOH, SDS, NaOCl, HCOOH, LpHse and Hellmanex. In contrast to previous find-
ings (Thomzig et al., 2014), both NaOH and SDS treatments did not show any
inactivation of ↵-synuclein propagation activity. Hellmanex and LpHse were found to
be equally ine cient. The only e cient decontaminants were NaOCl and HCOOH.
↵-synuclein coated beads treated with 2% NaOCl or 70% HCOOH showed a sig-
nificant reduction of propagation activity. The e ciency to inactivate ↵-synuclein
aggregates with hypochlorite was confirmed by two recent publications (Bousset
et al., 2016; Hughson et al., 2016). Similar to our findings, Bousset et al., 2016
showed that NaOCl can e ciently remove ↵-synuclein oligomers and fibrils from
stainless steel surfaces, but not from glass and plastic surfaces (Bousset et al.,
2016). The same study confirmed our results with respect to NaOH treatment being
ine cient. In contrast, the study showed e cient decontamination with SDS and
Hellmanex, while in our hands neither SDS nor Hellmanex treatment significantly
reduced the propagation activity. The observed discrepancies might be explained
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by the di erent methodologies used to assess decontamination e ciency. While I
measured the propagation activity remaining on the surfaces after decontamination
treatment, Bousset et al., 2016 determined the amount of ↵-synuclein aggregates
using fluorescence or absorbance measurements.
Further studies are needed to evaluate the e ciency of these and other decon-
taminants. In light of the increasing evidence suggesting prion-like transmission of
↵-synuclein pathology, the safety considerations for working with potentially infec-
tious ↵-synuclein aggregates should be carefully revisited. To ensure patient and
researcher safety, proper decontamination procedures should be introduced for the
cleaning of surgical and laboratory materials.
Towards a Diagnostic ↵-Synucleinopathy Blood Assay
The high sensitivity of the ↵-synuclein amyloid amplification assay makes it a useful
tool for the detection of small amounts of ↵-synuclein aggregates in patient tissues.
The detection of ↵-synuclein aggregates in easily accessible body fluids enables the
minimally invasive diagnosis of Parkinson’s disease and other ↵-synucleinopathies.
As an extension of previously published assays diagnosing ↵-synucleinopathies
from brain tissue and CSF samples (Fairfoul et al., 2016; Shahnawaz et al., 2017;
Sano et al., 2017), we aimed at detecting ↵-synuclein aggregates in blood. Recent
pathophysiologic studies revealed peripheral disease onset in the gastrointestinal
system years before first appearance in the central nervous system (Braak et al.,
2003a; Hilton et al., 2014; Stokholm et al., 2016). Besides neuron-to-neuron trans-
mission through the vagus nerve (Holmqvist et al., 2014; Ulusoy et al., 2017), the
systemic spreading of ↵-synuclein is hypothesised to occur through the blood stream
by crossing the blood-brain-barrier (Peelaerts et al., 2015). Therefore, we decided
to adapt the amplification assay to detect ↵-synuclein aggregates in the blood of
patients.
In a first experiment, I investigated the e ect of small amounts of blood added to the
↵-synuclein conversion reactions. The complex blood matrix was found to have a
strong inhibitory e ect on the propagon-catalysed conversion of ↵-synuclein. There-
fore, I investigated pretreatment strategies aimed at minimising the inhibitory e ect
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of the blood matrix enriching ↵-synuclein aggregates at the same time. A harsh
sarkosyl treatment solubilised most components of blood, and subsequent precipita-
tion of insoluble aggregates with NaPTA enriched ↵-synuclein aggregates, similar to
previously shown studies purifying prion aggregates from blood (Concha-Marambio
et al., 2016; Elder et al., 2015). In the ↵-synuclein amyloid amplification assay, most
PD patient samples showed partial reactivity with one or more (out of four) replicate
reactions being positive. In contrast, samples from healthy donors mainly lacked
propagation activity. Similar results were achieved with pretreatments for more
specific accumulation of ↵-synuclein aggregates from blood samples. ↵-Synuclein
aggregates were captured and enriched from blood with steel beads, similar to the
enrichment of blood prions with steel wires before RT-QuIC (Edgeworth et al., 2011).
Beads incubated with blood from healthy donors did not show any reactivity, while
beads incubated with PD patient blood showed little reactivity. A slightly higher prop-
agation reactivity of the PD blood samples was achieved by specifically enriching
↵-synuclein aggregates through immunoprecipitation with anti-↵-synuclein coupled
magnetic beads.
Taken together, this study provides evidence that we can specifically detect ↵-
synuclein aggregates in PD patient blood samples. However, the reliable detection
of the aggregates remains challenging. One possible explanation for the uncertain
diagnosis is the fact that the tests were performed with blood samples of patients
with unknown disease stage. The aggregate load in such samples might vary widely
and therefore cause inconsistent results. The use of samples with a known, high
amyloid content from patients with advanced synucleinopathy might lead to more
consistent results. Moreover, the detection sensitivity could potentially be improved
by further optimisation of pretreatment strategies. An increase in blood analyte
volume would possibly raise the number of propagating ↵-synuclein aggregates.
Combined with enrichment by immunoprecipitation this might lead to more sensitive
detection.
With improved reliability and robustness, the assay could serve as a tool for the
diagnosis of ↵-synucleinopathies similar to the RT-QuIC assay for CJD diagnostics.
The capability to use blood samples for diagnosis would present a major advance
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compared to the use of brain biopsies and CSF samples (Fairfoul et al., 2016;
Shahnawaz et al., 2017; Sano et al., 2017). An easy-to-use and minimally invasive
blood test would present a very powerful biochemical diagnostic tool that could
complement current clinical diagnostic tests.
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4.4 Materials and Methods
4.4.1 Expression and Purification of Human ↵-Synuclein
Construction of Plasmid Encoding the SNCA Gene
The pRK172 plasmid harbouring the human ↵-synuclein gene (SNCA), kindly pro-
vided by Prof. Kelvin Luk (University of Pennsylvania, Perelman School of Medicine),
was used as the template for mutagenesis. To avoid misincorporation of cysteine for
tyrosine at codon 136 (Masuda et al., 2006), codon 136 was mutated from Y136-TAC
to Y136-TAT by site-directed mutagenesis using the QuikChange II Site-Directed
Mutagenesis Kit (Agilent) with primers aSyn_c408t_for and aSyn_c408t_rev (see
Appendix) following the instruction manual. The sequence of the construct was
verified by automated Sanger sequencing at Microsynth (Balgach, Switzerland).
Expression and Purification of Human ↵-Synuclein
E. coli BL21(DE3)RIL harbouring the pRK172 plasmid encoding the human ↵-
synuclein gene (codon Y136-TAT) were grown overnight at 37  C in TB medium
containing 100 µg mL 1 ampicillin. Cells were harvested by centrifugation, resus-
pended in 10 mM Tris-HCl (pH 7.6), 750 mM NaCl, 1 mM EDTA, 1 mM PMSF,
complete EDTA-free protease inhibitor tablet (Roche), and lysed by five freeze-thaw
cycles using liquid nitrogen and tap warm water. Cell debris were removed by
centrifugation (12,000 g, 30 min, 4  C), and the supernatant was boiled for 15 min
at 99  C to heat-denature and precipitate unwanted proteins. Precipitates were
removed by centrifugation (12,000 g, 30 min, 4  C). Nucleic acids were removed with
streptomycin sulphate (10 mg mL 1) precipitation followed by centrifugation (12,000
g, 30 min, 4  C). For further purification, ↵-synuclein was salted out using ammonium
sulphate (361 mg mL 1) precipitation, and enriched by centrifugation (12,000 g,
30 min, 4  C). Pellets containing precipitated ↵-synuclein were resuspended in 10
mM Tris-HCl (pH 7.6), and dialysed overnight against 10 mM Tris-HCl (pH 7.6) to
remove remaining salts. The dialysed sample was loaded onto a Hi-Trap Q HP
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anion-exchange chromatography column (GE Healthcare) equilibrated with 10 mM
Tris-HCl (pH 7.6). After washing unbound materials with 5 column volumes of 10
mM Tris-HCl (pH 7.6), the protein was eluted with a linear salt gradient from 0 to 1
M of NaCl over 20 column volumes. Protein containing fractions were collected, and
analysed by SDS-PAGE. Fractions containing ↵-synuclein were pooled and dialysed
overnight against 25 mM Tris-HCl (pH 7.4), 100 mM NaCl. The dialysed sample was
loaded onto a HiLoad 26/60 Superdex75 size exclusion column (GE Healthcare),
and eluted with 25 mM Tris-HCl (pH 7.4), 100 mM NaCl at a flow rate of 2 mL min 1.
Protein containing fractions were analysed by SDS-PAGE, and fractions containing
↵-synuclein were pooled. The purification yields were 90–120 mg L 1 of bacterial
culture. The purity of the protein was verified by SDS-PAGE and ESI-MS (Functional
Genomics Center Zurich). Protein concentrations were measured by absorbance at
280 nm using a molar extinction coe cient ("280) of 5960 M 1cm 1.
4.4.2 Preparation of Preformed ↵-Synuclein Fibrils
Highly pure, monomeric ↵-synuclein was thawed, adjusted to 5 mg mL 1 in a final
volume of 500 µL using PBS in a Protein LoBind tube (Eppendorf). To reconstitute
the protein into amyloid fibrils, the protein was incubated at 37  C under vigorous
shaking at 1000 rpm for 7 d inside a thermomixer with heatable lid (Volpicelli-Daley et
al., 2014). The fibrils were aliquoted and stored at -20  C. Low temperature storage
is crucial to prevent the dissociation of fibrils and thus the loss in propagation activity
as described earlier (Bousset et al., 2013; Volpicelli-Daley et al., 2014).
4.4.3 Fibril Sedimentation Assay
Pelletable, active↵-synuclein fibrils were confirmed as previously published (Volpicelli-
Daley et al., 2014). Briefly, 20 µL of fibrils were centrifuged at 100,000 g for 60 min
at room temperature. The supernatant was removed and mixed with 2X Laemmli
bu er for SDS-PAGE analysis. The pellet was resuspended in 20 µL PBS, and
again centrifuged at 100,000 g for 60 min at room temperature. After centrifugation
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the supernatant was discarded, and the pellet was resuspended in 20 µL PBS and
mixed with 2X Laemmli bu er. Both collected supernatant and pellet fractions were
analysed by SDS-PAGE.
4.4.4 ↵-Synuclein Amyloid Amplification Assay
The ↵-synuclein amyloid amplification assay was performed using recombinant hu-
man ↵-synuclein as substrate. Recombinant human ↵-synuclein was thawed and fil-
tered using 50 kDa Amicon Ultra centrifugal filters (Millipore, Prod. No. UFC505096)
to remove potential aggregated protein. The protein was adjusted to a final con-
centration of 10 µM in 25 mM NaOAc (pH 5.2) containing 10 µM thioflavin T in a
total reaction volume of 30 µL (including seed volume). Amplification reactions were
seeded with 2.5 µL of preformed ↵-synuclein fibrils, patient samples or with bu er
for the unseeded control reaction. All amplification reactions were performed in
quadruplicate in black 96-well half area polystyrene microplates (Corning, Prod. No.
3880) covered with a sealing tape (Sarstedt, Prod. No. 95.1999). The reactions
were amplified over 24 h at 60  C with alternating cycles of 150 s shaking at 1100
rpm in double orbital mode and 150 s resting using a FLUOstar Omega microplate
reader (BMG Labtech). A low intensity shaking of 60 s shaking at 100 rpm was
used for blood samples pretreated by immunoprecipitation to prevent spontaneous
aggregation caused by the magnetic beads. The formation of new aggregates was
followed real-time by measuring thioflavin T fluorescence (ex/em filters 450/480 nm)
every 5 min in bottom read mode.
4.4.5 Steel Beads ↵-Synuclein Amyloid Amplification Assay
All coatings and decontamination treatments of steel beads were performed by
Daniel Heinzer. Steel beads were dissolved in PBS, diluted to the final bead number
and stored at -20  C until usage. All samples were treated identically and diluted
using the same dilution steps to minimise the error in bead number arising from
inaccurate pipetting. In addition, samples were thoroughly vortexed before every
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pipetting to suspend the beads. Amplification was performed as described in the
section ’↵-Synuclein Amyloid Amplification Assay’. Amplification reactions were
seeded with 2.5 µL of the bead samples in a total reaction volume of 30 µL.
4.4.6 Mouse Blood Samples
Mouse blood was collected from adult C57BL/6J mice, and processed to plasma,
serum and red blood cells.
Preparation of Blood Plasma
Mouse blood was collected into tubes containing 17 IU mL 1 sodium heparin (Braun),
and mixed by inverting the tube 8–10 times. Blood plasma was separated immedi-
ately after collection (at latest 1 h after sample collection) by centrifugation at 2000
g for 10 min at 4  C. The supernatant (blood plasma) was collected, aliquoted and
stored at -20  C until usage.
Preparation of Blood Serum
Mouse blood was collected, and allowed to clot for 30–40 min at room temperature.
The clot was removed by centrifugation at 2000 g for 10 min at 4  C. The supernatant
(blood serum) was collected, aliquoted and stored at -20  C until usage.
Preparation of Red Blood Cells
Mouse blood was collected into tubes containing 17 IU mL 1 sodium heparin (Braun),
and mixed by inverting the tube 8–10 times. Red blood cells were separated from
blood plasma immediately after collection (at latest 1 h after sample collection) by
centrifugation at 2000 g for 10 min at 4  C. The red blood cells collected in the pellet
fraction were washed three times in PBS (pH 7.4, Ca2+- and Mg2+-free), aliquoted
and stored at -20  C until usage.
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4.4.7 Patient Samples
Ethics Statement and Patient Population
Ethics approval for the use of patient samples was given by the cantonal ethics
commission Zurich under the project number 2017-00760. According to the ethics
approval, patient blood drawn for diagnostic purposes can be further reused for
research purposes after diagnostic application. All patients have given written
informed consent for the reuse of their biological specimens.
Blood samples from patients su ering from Parkinson’s disease were provided by the
Institute of Neurology at the University Hospital Zurich (Dr. med. Evdokia Efthymiou,
Prof. Dr. med. Christian Baumann). Patients were diagnosed by the clinicians of
the Institute of Neurology according to standard clinical diagnostic criteria, and most
of them were in the hospital to undergo deep brain stimulation surgery.
Blood samples from healthy donors were obtained from the Swiss Transfusion SRC
Zurich.
Blood Samples
Blood was collected into Vacutainer® blood collection tubes (Becton Dickinson,
Prod. No. 366643) containing 1.8 mg mL 1 EDTA, and stored at -20  C until usage.
Samples were thawed at 37  C directly before analysis.
4.4.8 Blood Pretreatment of Patient Samples
Sarkosyl Solubilisation
To solubilise patient blood samples, 600 µL of EDTA whole blood was mixed with 600
µL of a 30% sarkosyl (N-lauroylsarcosine sodium salt) stock solution (Sigma, Prod.
No. 61747), and the mixture was incubated for 10 min at room temperature, 650 rpm.
To collect insoluble particles, the mixture was ultracentrifuged at 100,000 g for 1 h at
4  C. The pelleted fraction was resuspended in 1 mL of 50 mM NaOAc (pH 5.2) for
washing, and centrifuged again at 100,000 g, 25 min, 4  C). The supernatant was
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discarded, and the pellet was resuspended in 50 µL of 50 mM NaOAc (pH 5.2). The
resuspended pellets were vortexed vigorously before addition to the amplification
reaction.
NaPTA Precipitation
To solubilise blood samples before precipitation with sodium phosphotungstic acid
(NaPTA), 600 µL of EDTA whole blood was mixed with 200 µL of a 8% sarkosyl
(Sigma, Prod. No. 61747) stock solution to a final sarkosyl concentration 2%,
and solubilised for 2 h at 37  C, 1200 rpm. After solubilisation, 800 µL of a 4%
NaPTA (Sigma, Prod. No. P6395) were added for precipitation with a final NaPTA
concentration of 2% overnight at 37  C, 1200 rpm. To collect precipitates, the mixture
was centrifuged at 15,000 g for 30 min at 25  C. The supernatant was removed and
the pellet resuspended in 2% sarkosyl, 2% NaPTA and incubated for another 1 h at
37  C, 1200 rpm. Precipitates were collected by centrifugation at 15,000 g for 30
min at 25  C. The pelleted precipitates were washed with 1 mL of PBS, centrifuged
(15,000 g, 30 min, 25  C), and resuspended in 50 µL of PBS. The resuspended
pellets were used to seed the amplification reactions.
Steel beads capturing
316L grade stainless steel beads (ThyssenKrupp) with an average bead diameter
of <20 µm were used for capturing of ↵-synuclein aggregates from human blood.
Beads were autoclaved at 121  C for 20 min before use. For capturing, 250 µg
of autoclaved beads were mixed with 1 mL of EDTA whole blood, and the mixture
was incubated overnight on a rotating wheel at room temperature. After incubation,
the beads were collected with a magnet, and the blood supernatant was removed.
The beads were resuspended in 500 µL of PBS and used to seed the amplification
reactions.
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Immunoprecipitation
Supramagnetic, 2.8 µm diameter sheep anti mouse IgG Dynabeads coupled to the
anti-↵-synuclein antibody syn211 (Thermo Fisher Scientific, Prod. No. 11202D)
were used to specifically capture ↵-synuclein from human blood. For the coating,
beads were resuspended by vortexing for 30 s, and 2 x 200 µL of beads were
transferred to two tubes to prepare beads for four di erent samples. The beads
were collected with a magnet, and the bead storage bu er was discarded. The
beads were washed twice with 0.1% BSA in PBS, before addition of the primary
anti-↵-synuclein antibody syn211 (8 µg of Ab in 0.1% BSA in PBS per 200 µg of
beads) into one of the two tubes and incubation for 2 h on a rotating wheel at 4  C.
The other tube with beads was incubated with 0.1% BSA in PBS (no primary Ab)
for 2 h on a rotating wheel at 4  C. After incubation, the beads in both tubes were
collected with a magnet, and washed 3x with 1 mL of 0.1% BSA in PBS. After the
last washing step, the beads were resuspended in 2 x 200 µL of 0.1% BSA in PBS.
For the immunoprecipitation, 500 µL of EDTAwhole blood was incubated for 30min at
room temperature on a rotating wheel with 500 µL of 50 mM Tris-HCl (pH 7.4), 1%NP-
40, 150 mM NaCl and protease inhibitor (Roche). Following this preincubation, BSA
was added to a final concentration of 0.5%, and 50 µL of uncoated Dynabeads were
added for preclearing of the blood for 45 min on a rotating wheel at room temperature.
After preclearing, beads with unspecifically bound material were removed with a
magnet, and the supernatant was added to 50 µL of Dynabeads coated with syn211
anti-↵-synuclein antibodies for immunoprecipitation. The samples were incubated
overnight at room temperature on a rotating wheel. The next day, the beads were
collected with a magnet, washed 2x with 1 mL of 50 mM Tris-HCl (pH 7.4), 0.5%
NP-40, 150 mM NaCl containing 0.5% BSA, then 3x with 1 mL of the same bu er
without BSA, and finally 2x with 1 mL of PBS. After the last washing step, the
supernatant was discarded, an the beads were resuspended in 50 µL of PBS for
propagation analysis with the ↵-synuclein amyloid amplification assay.
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5Conclusions and Perspectives
Amyloid amplification assays recapitulate the self-replicating properties of amyloid
proteins. In the framework of this PhD study, I was able to advance amyloid am-
plification assays in di erent amyloid systems. By combining the power of digital
microfluidics with the concept of amyloid self-propagation, I developed a quantitative
assay to determine absolute numbers of amyloid propagons in a test sample. The
assay is capable of detecting single propagation units, and precisely quantifying
propagons at low concentrations. Further work included amplification of the disease-
related proteins, prion protein and ↵-synuclein. I implemented the RT-QuIC, a prion
amplification assay, and applied it for diagnostic and scientific applications. More-
over, I established an amplification assay for ↵-synuclein fibrils. The ↵-synuclein
assay was used to study potential decontaminants for the inactivation of ↵-synuclein
aggregates. In addition, di erent strategies were tested to develop a diagnostic
blood test for ↵-synucleinopathies using the ↵-synuclein assay. Both, the prion and
the ↵-synuclein amplification assays provide powerful tools to study diagnostic and
scientific aspects of amyloid propagation.
The digitisation of amyloid amplification assays for pathologic proteins might repre-
sent the next step towards a new era of molecular diagnostics of neurodegenerative
disorders. The absolute quantification of disease-related amyloid propagons holds
great potential for applications in preclinical point-of-care diagnostics and for studying
disease progression. Moreover, the ability to diagnose neurodegenerative disor-
ders in patient blood samples at presymptomatic stages would represent a major
breakthrough in the diagnosis of protein misfolding and aggregation diseases. More
fundamentally, the further advancement of digital amyloid amplification assays will
help us to develop a more complete understanding of the molecular mechanisms
underlying self-propagation and infectivity in neurodegenerative diseases.
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AAppendix
A.1 Protein Parameters
Protein MW "280 isoelectric #aa
(Da) M 1cm 1 point
human insulin 5,808 5,270 5.39 51
insulin glargine 6,063 4,930 6.88 53
human ↵-synuclein 14,460 5,960 4.67 140
mouse PrP 23,019 63,370 9.56 209
hamster PrP 22,973 61,880 9.58 209
A.2 Primer Sequences
aSyn_c408t_for: 5’-ggaagggtatcaagactatgaacctgaagcctaagaa-3’
37 bp, Tm: 78.28 C.
aSyn_c408t_rev: 5’-ttcttaggcttcaggttcatagtcttgatacccttcc-3’
37 bp, Tm: 78.28 C.
All primers were synthesised by Microsynth (Balgach, Switzerland).
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A.3 Gene and Protein Sequences of Human
↵-Synuclein
DNA Sequence of aSyn TAC136TAT
1 11 21 31 41
atggatgtat tcatgaaagg actttcaaag gccaaggagg gagttgtggc
51 61 71 81 91
tgctgctgag aaaaccaaac agggtgtagc agaagcagca ggaaagacaa
101 111 121 131 141
aagagggtgt tctctatgta ggctccaaaa ccaaggaggg agtggtgcat
151 161 171 181 191
ggtgtggcaa cagtggctga gaagaccaaa gagcaagtga ctaatgttgg
201 211 221 231 241
aggagcagtg gtgacgggtg tgacagcagt agcccagaag acagtggagg
251 261 271 281 291
gagcagggag cattgcagca gccactggct ttgtcaaaaa ggaccagttg
301 311 321 331 341
ggcaagaatg aagaaggagc cccacaggaa ggaattctgg aagatatgcc
351 361 371 381 391
tgtggatcct gacaatgagg cttatgaaat gccttctgag gaagggtatc
401 411
aagactatga acctgaagcc
Amino Acid Sequence of aSyn
1 11 21 31 41
MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH
51 61 71 81 91
GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL
101 111 121 131
GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
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